Drugs for treating ryanodine receptor-related disorders
Patent Information
- Application Number
- JP2023553166
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-17
- Filing Date
- 2021-11-16
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Mutations and post-translational modifications of ryanodine receptors (RyR) lead to increased channel leakage, causing decreased intracellular calcium levels and resulting in weakened muscle contractions and various pathological outcomes, including cardiac arrhythmias and neurodegenerative diseases.
Development of 1,4-benzothiazepine derivatives, known as Rycal compounds, which stabilize RyR channels by enhancing the binding of calstabin proteins, thereby reducing calcium leakage and restoring normal channel function.
Rycal compounds effectively stabilize RyR channels, improving muscle contraction and reducing the risk of cardiac arrhythmias and neurodegenerative diseases by maintaining appropriate calcium levels within cells.
Smart Images

Figure 2022108945000001 
Figure 2022108945000002 
Figure 2022108945000003
Abstract
Description
[Technical Field]
[0001] cross reference
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 114,724, filed on 17 November 2020, which is incorporated herein by reference in its entirety. [Background technology]
[0002]
[0002] The sarcoplasmic reticulum (SR) is particularly rich in special intracellular calcium (Ca 2+ It is an intracellular structure that functions as a storage area. The ryanodine receptor (RyR) is a channel located in the sarcoplasmic receptacle (SR) that opens and closes, allowing Ca to flow from the SR to the intracellular cytoplasm. 2+ It controls the release of Ca from SR to the cytoplasm. 2+ The release of cytoplasmic Ca 2+ The concentration is increased. The probability of RyR opening is that a given RyR opens at any given moment, and therefore Ca from SR to the cytoplasm. 2+ This refers to the potential for the release of RyR. Three RyR isoforms are known. RyR1 is the dominant isoform expressed in mammalian skeletal muscle, RyR2 is mainly found in cardiac muscle, while RyR3 expression is low in skeletal muscle.
[0003]
[0003] Ca from SR 2+ RyR release is regulated by several RyR-binding proteins. Calstabin 1 (FKBP12) and Calstabin 2 (FKBP12.6) stabilize the closed state of RyR1 and RyR2, respectively. Mutations in RyR1 or RyR2 are characterized by decreased binding of Calstabin 1 or Calstabin 2, respectively, and improper channel opening unrelated to contraction signals. This channel opening is further exacerbated by post-translational modifications of the RyR channel, such as PKA-phosphorylation, oxidation, or nitrosylation. The resulting dissociation of Calstabin can lead to leaky channels exhibiting pathologically increased opening probability at rest. 2+ The leakage is from SR Ca2+ resulting in a decrease in content and less Ca available for release 2+ which leads to less of it and, as a result, weaker muscle contractions.
Summary of the Invention
Means for Solving the Problems
[0004]
[0004] In some embodiments, formula (I):
[0005]
Chemical Formula
[0006] (wherein - each R 1a , R 1b , R 1c , and R 1d is independently, each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 , -SO3H, -SO2R 6 , -OSO2R 6 , -S(O)R 6 , or -SR 7 , or hydrogen or halogen, - R 2 is independently, each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -C(O)NR 3 R 4 , -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8 , or -C(O)C(O)OR 8 , - each R 3 and R 4Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 , R 7 , and R 8 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a pharmaceutically acceptable salt thereof, however, (a)(i)R 1a , R 1b , R 1c , and R 1d (ii)R 1b (iii)R 2 Compounds in which -C(O)OtBu or -C(O)OCH2Ph are excluded. (b)R 1d When R is methyl, 2 It is not 4-methoxybenzyl, (c)R 1a When is methyl, Cl, CN, or F, or R 1b When R is Br, 2 It is not methyl, -C(=O)H, -C(=O)Me, -C(=O)Et, or -C(=O)Ph. Compounds subject to the condition, or pharmaceutically acceptable salts thereof, are described herein.
[0007]
[0005] In some embodiments, pharmaceutical compositions in unit dosage forms comprising a pharmaceutically acceptable excipient and a compound of the present disclosure are described herein.
[0008]
[0006] In some embodiments, methods for a medical condition, such as a condition related to the ryanodine receptor, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of the present disclosure are described herein. Incorporation by reference
[0007] All publications, patents, and patent applications mentioned herein are incorporated herein by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Brief Description of the Drawings
[0009] [Figure 1]
[0008] Compound 2 improves calstabin 2 / RyR2 binding in brain microsomal lysates from Huntington's disease (HD) patients. [Figure 2]
[0009] Rycal (Compound 2 and reference compound S107) increases calstabin 2 binding to HD microsomes in a concentration-dependent manner. ◆Compound 2; ■S107. [Figure 3]
[0010] Compound 2 reduces calcium leakage from HD microsomes. ◆HD; ■Control; ▲HD / Compound 2. Figure 3a: Fluo-4 signal over time (ratio to initial signal). Figure 3b: Ca2+ leakage (rate of signal increase).
Modes for Carrying Out the Invention
[0010]
[0011] The present disclosure provides 1,4-benzothiazepine derivatives, and pharmaceutically acceptable salts thereof. In some embodiments, the compounds are ryanodine receptor (RyR) calcium channel stabilizers called Rycal. The present disclosure further provides methods of using these compounds for treating medical conditions, such as conditions related to the ryanodine receptor.
[0011]
[0012] In some embodiments, the compounds of the Disclosure are brain-penetrating and suitable for the treatment of central nervous system (CNS)-related disorders and conditions. In some embodiments, the compounds of the Disclosure are brain-penetrating, metabolically stable, and pharmacologically active in treating CNS conditions associated with ryanodine receptors. Compounds of the Disclosure
[0013] In some embodiments, this disclosure relates to formula (I):
[0012] [ka]
[0013] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - R 2 These are, respectively, independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, and -C(O)NR 3 R 4 -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8 , or -C(O)C(O)OR 8 And, - Each R 3 and R4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 , R 7 , and R 8 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or provide a pharmaceutically acceptable salt thereof.
[0014]
[0014] In some embodiments, R 1a , R 1b , R 1c , and R 1d Compounds of formula (I) in which each of are hydrogen are excluded. In some embodiments, R 1b Compounds of formula (I) in which is OH or methoxy are excluded. In some embodiments, R 2 Compounds of formula (I) where is -C(O)OtBu or -C(O)OCH2Ph are excluded. In some embodiments, R 1d When R is methyl, 2 It is not 4-methoxybenzyl. In some embodiments, R 1a When is methyl, Cl, CN, or F, or R 1b When R is Br, 2 It is not methyl, -C(=O)H, -C(=O)Me, -C(=O)Et, or -C(=O)Ph.
[0015]
[0015] In some embodiments, R1a is an electron-withdrawing group. In some embodiments, R 1b is an electron-withdrawing group. In some embodiments, R 1c is an electron-withdrawing group. In some embodiments, R 1d is an electron-withdrawing group.
[0016]
[0016] In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is haloalkyl. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is trifluoromethyl. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is halogen. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is fluoro. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is chloro. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is bromo. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is iodo. In some embodiments, R 1a , R 1b , R 1c , and R 1d at least one of is haloalkoxy. In some embodiments, R 1a , R 1b , R 1c, and R 1d At least one of them is trifluoromethoxy.
[0017]
[0017] In some embodiments, R 1a is trifluoromethyl. In some embodiments, R 1b is trifluoromethyl. In some embodiments, R 1c is trifluoromethyl. In some embodiments, R 1d is trifluoromethyl. In some embodiments, R 1a is trifluoromethoxy. In some embodiments, R 1b is trifluoromethoxy. In some embodiments, R 1c is trifluoromethoxy. In some embodiments, R 1d It is trifluoromethoxy.
[0018]
[0018] In some embodiments, R 1a is fluoro. In some embodiments, R 1b is fluoro. In some embodiments, R 1c is fluoro. In some embodiments, R 1d is fluoro. In some embodiments, R 1a is chloro. In some embodiments, R 1b is chloro. In some embodiments, R 1c is chloro. In some embodiments, R 1d is chloro. In some embodiments, R 1a is bromo. In some embodiments, R 1b is bromo. In some embodiments, R 1c is bromo. In some embodiments, R 1d is bromo. In some embodiments, R 1a is iodine. In some embodiments, R 1b is iodine. In some embodiments, R 1cis iodine. In some embodiments, R 1d It is iodine.
[0019]
[0019] In some embodiments, R 2 is -C(O)NR 3 R 4 The compound is given by formula (I')
[0020] [ka]
[0021] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a pharmaceutically acceptable salt thereof.
[0022]
[0020] In some embodiments, (i)R 1a , R 1b , R 1c , and R 1d Compounds of formula (I') in which each of are hydrogen are excluded. In some embodiments, R 1b Compounds of formula (I') where is methoxy are excluded.
[0023]
[0021] In some embodiments, R 3 and R 4 R 3 and R 4 Together with the bonded nitrogen atom, it forms an unsubstituted heterocycle. In some embodiments, R 3 and R 4 R 3 and R 4 Together with the bonded nitrogen atom, it forms a substituted heterocycle. In some embodiments, R 3 and R 4 R 3 and R 4 Together with the bonded nitrogen atom, it forms an unsubstituted piperazinyl ring. In some embodiments, R 3 and R 4 R 3 and R 4 Together with the bonded nitrogen atom, it forms a substituted piperazinyl ring.
[0024]
[0022] In some embodiments, the present disclosure relates to formula (II)
[0025] [ka]
[0026] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - R 9 These are, respectively, independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8, or hydrogen, - Each R 10 These are independently unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -NR 3 R 4 , -OR 5 , or -SR 7 And, - The compound (where m is 0, 1, 2, 3, 4, 5, 6, 7, or 8) or provide a pharmaceutically acceptable salt thereof.
[0027]
[0023] In some embodiments, R 1a , R 1b , R 1c , and R 1d Compounds of formula (II) in which each of are hydrogen are excluded. In some embodiments, R 1b Compounds of formula (II) in which is methoxy are excluded.
[0028]
[0024] In some embodiments, the present disclosure relates to formula (III)
[0029] [ka]
[0030] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7, or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or provide a pharmaceutically acceptable salt thereof.
[0031]
[0025] In some embodiments, (i)R 1a , R 1b , R 1c , and R 1d Compounds of formula (III) in which each of are hydrogen are excluded. In some embodiments, R 1b Compounds of formula (III) where is methoxy are excluded.
[0032]
[0026] In some embodiments, the present disclosure is expressed by formula (IV):
[0033] [ka]
[0034] (In the formula, - Each R 1 These are independently halogens, haloalkyls, and haloalkyloxys. - Compounds of n (where n is 1, 2, 3, or 4) or provide a pharmaceutically acceptable salt thereof.
[0035]
[0027] In some embodiments, R 1 is a halogen. In some embodiments, R 1 is fluoro. In some embodiments, R 1 is chloro. In some embodiments, R 1 is bromo. In some embodiments, R 1 is iodine. In some embodiments, R 1 is a haloalkyl. In some embodiments, R 1 is a halomethyl. In some embodiments, R 1 is CF3. In some embodiments, R 1 R is a haloalkyloxy. In some embodiments, R 1 is halomethoxy. In some embodiments, R 1 It is trifluoromethoxy.
[0036]
[0028] In some embodiments, n is 1. In another embodiment, n is 2. In another embodiment, n is 3. In another embodiment, n is 4.
[0037]
[0029] In some embodiments, n is 1 and R 1 This is the 6th position of the benzothiazepine ring, and the compound is represented by the formula:
[0038] [ka]
[0039] It is a compound of or a pharmaceutically acceptable salt thereof.
[0040]
[0030] In some embodiments, n is 1 and R 1 It is at position 7 of the benzothiazepine ring, and the compound is given by formula:
[0041] [ka]
[0042] It is a compound of or a pharmaceutically acceptable salt thereof.
[0043]
[0031] In some embodiments, n is 1 and R 1 This is the 8th position of the benzothiazepine ring, and the compound is given by the formula:
[0044] [ka]
[0045] It is a compound of or a pharmaceutically acceptable salt thereof.
[0046]
[0032] In some embodiments, n is 1 and R 1 This is the 9th position of the benzothiazepine ring, and the compound is represented by the formula:
[0047] [ka]
[0048] It is a compound of or a pharmaceutically acceptable salt thereof.
[0049]
[0033] In some embodiments, n is 2 and R 1 These are the 7th and 8th positions of the benzothiazepine ring, and the compound is given by the formula:
[0050] [ka]
[0051] It is a compound of or a pharmaceutically acceptable salt thereof.
[0052]
[0034] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (1)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0053] [ka]
[0054]
[0035] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(7-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (2)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0055] [ka]
[0056]
[0036] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(9-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (3)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0057] [ka]
[0058]
[0037] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(7-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (4)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0059] [ka]
[0060]
[0038] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(6-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (5)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0061] [ka]
[0062]
[0039] In some embodiments, the present disclosure provides a compound which is (7,8-difluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone (compound (6)) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0063] [ka]
[0064]
[0040] In some embodiments, the present disclosure provides a compound which is (6-chloro-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone (compound (7)) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0065] [ka]
[0066]
[0041] In some embodiments, the present disclosure provides a compound which is piperazine-1-yl(6-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (compound (8)), or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0067] [ka]
[0068]
[0042] In some embodiments, the present disclosure provides a compound which is (6-bromo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone (compound (9)) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0069] [ka]
[0070]
[0043] In some embodiments, the present disclosure provides a compound which is (6-iodo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone (compound (10)) or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutically acceptable salt is a hydrochloride salt.
[0071] [ka]
[0072]
[0044] Some of the sites described herein may be substituted or unsubstituted. Non-limiting examples of optional substituents include hydroxyl groups, sulfhydryl groups, halogens, amino groups, nitro groups, nitroso groups, cyano groups, azide groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxyaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, ureido groups, epoxy groups, and ester groups. Other non-limiting examples of optional substituents include halogens, haloalkyls, hydroxys, alkoxys, haloalkoxys, cycloalkyls, aryls, heterocyclyls, heteroaryls, amides, alkylamides, dialkylamides, nitros, aminos, cyanos, azides, oxos, alkylaminos, dialkylaminos, carboxyls, thios, thioalkyls, and thioaryls.
[0073]
[0045] Non-limiting examples of alkyl groups include linear, branched, and cyclic alkyl groups. Alkyl groups include, for example, substituted or unsubstituted C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 It could be the basis for...
[0074]
[0046] Non-limiting examples of linear alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
[0075]
[0047] Branched alkyl groups include any linear alkyl group substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl. Non-limiting examples of substituted alkyl groups include hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1-chloroethyl, 2-hydroxyethyl, 1,2-difluoroethyl, and 3-carboxypropyl.
[0076]
[0048] Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. Cyclic alkyl groups also include condensed bicyclic, crosslinked bicyclic, and spiro-bicyclic, as well as higher-order condensed, crosslinked, and spiro systems. Cyclic alkyl groups can be substituted with any number of linear, branched, or cyclic alkyl groups. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cyclopropane-1-yl, cyclopropane-2-en-1-yl, cyclobutyl, 2,3-dihydroxycyclobuta-1-yl, cyclobuta-2-en-1-yl, cyclopentyl, cyclopenta-2-en-1-yl, cyclopenta-2,4-dien-1-yl, cyclohexyl, cyclohexa-2-en-1-yl, cycloheptyl, cyclooctanyl, 2,5-dimethylcyclopenta-1-yl, 3,5-dichlorocyclohexa-1-yl, 4- This includes hydroxycyclohexa-1-yl, 3,3,5-trimethylcyclohexa-1-yl, octahydropentalenyl, octahydro-1H-indenyl, 3a,4,5,6,7,7a-hexahydro-3H-inden-4-yl, decahydroazlenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, 1,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.
[0077]
[0049] Non-limiting examples of alkenyl and alkenylene groups include linear, branched, and cyclic alkenyl groups. One or more olefins of an alkenyl group may be, for example, E, Z, cis, trans, terminal, or exo-methylene. Alkenyl or alkenylene groups may be, for example, substituted or unsubstituted C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C20 , C 21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 It may be a group of alkenyl and alkenylene groups. Non-limiting examples of alkenyl and alkenylene groups include ethenyl, propa-1-en-1-yl, isopropenyl; buta-1-en-4-yl, 2-chloroethenyl, 4-hydroxybuten-1-yl, 7-hydroxy-7-methylocta-4-en-2-yl, and 7-hydroxy-7-methylocta-3,5-dien-2-yl.
[0078]
[0050] Non-limiting examples of alkynyl or alkynylene groups include linear, branched, and cyclic alkynyl groups. The triple bond of the alkynyl (alkylnyl) or alkynylene group can be internal or terminal. The alkynyl (alkylnyl) or alkynylene group can be, for example, substituted or unsubstituted C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , C 12 , C 13 , C 14 , C 15 , C 16 , C 17 , C 18 , C 19 , C 20 , C21 , C 22 , C 23 , C 24 , C 25 , C 26 , C 27 , C 28 , C 29 , C 30 , C 31 , C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C 40 , C 41 , C 42 , C 43 , C 44 , C 45 , C 46 , C 47 , C 48 , C 49 , or C 50 It may be a group of alkynyl or alkynylene groups. Non-limiting examples of alkynyl or alkynylene groups include ethinyl, propa-2-in-1-yl, propa-1-in-1-yl, and 2-methylhexa-4-in-1-yl; 5-hydroxy-5-methylhexa-3-in-1-yl, 6-hydroxy-6-methylhepta-3-in-2-yl, and 5-hydroxy-5-ethylhepta-3-in-1-yl.
[0079]
[0051] The halo group may be, for example, chloro, bromo, fluoro, or iodine. A haloalkyl group may be any alkyl group substituted with any number of halogen atoms, for example, fluorine, chlorine, bromine, and iodine atoms. A haloalkenyl group may be any alkenyl group substituted with any number of halogen atoms. A haloalkynyl group may be any alkynyl group substituted with any number of halogen atoms. Non-limiting examples of haloalkyl groups include trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, difluoromethyl, chlorodifluoromethyl, pentafluoroethyl, 1,1-difluoroethylbromomethyl, chloromethyl, fluoromethyl, and iodomethyl.
[0080]
[0052] The alkoxy group may be, for example, an oxygen atom substituted with any alkyl group, alkenyl group, or alkynyl group. Ethers or ether groups include alkoxy groups. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy. The alkoxy group may be, for example, substituted or unsubstituted. The alkoxy group may be substituted with, for example, oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, and heteroaryl.
[0081]
[0053] A haloalkoxy group is an alkoxy group substituted with one or more halogen atoms, namely F, Cl, Br, or I. Non-limiting examples of haloalkoxy groups include trifluoromethoxy, trichloromethoxy, tribromomethoxy, triiodomethoxy, trifluoroethoxy, trichloroethoxy, tribromoethoxy, triiodomethoxy, trifluoroethoxy, trichloroethoxy, tribromopropoxy, triiodopropoxy, trifluoroisopropoxy, trichloromisopropoxy, tribromoisopropoxy, triiodoisopropoxy, trifluoroisobutoxy, trichloromisobutoxy, tribromoixobutoxy, and triiodoisobutoxy. Haloalkoxy groups can be substituted with, for example, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl. For example, the halogen or hydrogen group of the haloalkoxy group can be optionally substituted with amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl compounds.
[0082]
[0054] The aryl group may be heterocyclic or nonheterocyclic. The aryl group may be monocyclic or polycyclic. The aryl group may be substituted with any number of substituents described herein, such as hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms. Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl. Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-tert-butylphenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)phenyl, 4-(trifluoromethoxy)phenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2-iodophenyl, 3-iodophenyl, 4-iodophenyl, 2-methylphenyl, 3-fluorophenyl, 3-methylphenyl, 3-methoxyphenyl, 4-fluorophenyl, 4-methylphenyl, 4-methoxyphenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 4-hydroxyphenyl, 2 -Methoxyphenyl, 3-Methoxyphenyl, 4-Methoxyphenyl, 2,3-Dimethoxyphenyl, 3,4-Dimethoxyphenyl, 3,5-Dimethoxyphenyl, 2,4-Difluorophenyl, 2,5-Difluorophenyl, 2,6-Difluorophenyl, 2,3,4-Trifluorophenyl, 2,3,5-Trifluorophenyl, 2,3,6-Trifluorophenyl, 2,4,5-Trifluorophenyl, 2,4,6-Trifluorophenyl, 2,4-Dichlorophenyl, 2,5-Dichlorophenyl, 2,6-Dichlorophenyl, 3,4-Dichlorophenyl, 2,3,4-Trichlorophenyl, 2,3,5-Trichlorophenyl, 2,3,6-Trichlorophenyl, 2,4,5-Trichlorophenyl, 3,4,5-Trichlorophenyl, 2,4,6-Trichlorophenyl, 2,3,It contains 4-trimethylphenyl, 2,3,5-trimethylphenyl, 2,3,6-trimethylphenyl, 2,4,5-trimethylphenyl, 2,4,6-trimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-ethylphenyl, 2,3-diethylphenyl, 2,4-diethylphenyl, 2,5-diethylphenyl, 2,6-diethylphenyl, 3,4-diethylphenyl, 2,3,4-triethylphenyl, 2,3,5-triethylphenyl, 2,3,6-triethylphenyl, 2,4,5-triethylphenyl, 2,4,6-triethylphenyl, 2-isopropylphenyl, 3-isopropylphenyl, and 4-isopropylphenyl.
[0083]
[0055] Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(N-methylamino)phenyl, 2-(N,N-dimethylamino)phenyl, 2-(N-ethylamino)phenyl, 2-(N,N-diethylamino)phenyl, 3-aminophenyl, 3-(N-methylamino)phenyl, 3-(N,N-dimethylamino)phenyl, 3-(N-ethylamino)phenyl, 3-(N,N-diethylamino)phenyl, 4-aminophenyl, 4-(N-methylamino)phenyl, 4-(N,N-dimethylamino)phenyl, 4-(N-ethylamino)phenyl, and 4-(N,N-diethylamino)phenyl.
[0084]
[0056] The aryloxy group may be, for example, an oxygen atom substituted with any aryl group. Ethers or ether groups include aryloxy groups. The aryloxy group may be substituted or unsubstituted. The aryloxy group may be substituted with, for example, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl. For example, the halogen group or hydrogen group of a haloalkoxy group may be optionally substituted with amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, or heteroaryl.
[0085]
[0057] A heterocycle can be any ring containing a ring atom other than carbon, e.g., N, O, S, P, Si, B, or any other heteroatom. A heterocycle can be substituted with any number of substituents, e.g., alkyl groups and halogen atoms. A heterocycle can be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include piperazine, pyrrole, pyrrolidine, pyridine, piperidine, succinamide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.
[0086]
[0058] Non-limiting examples of heterocycles (heterocyclils) include: a heterocyclic unit having a single ring containing one or more heteroatoms, non-limiting examples of which include diazilinyl, azilidinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, oxathiazolidinyl, oxazolidinyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidine-2-onyl, 2,3 ii) a heterocyclic unit having two or more rings, one of which is a heterocycle, non-limiting examples of which include hexahydro-1H-pyrrolizinyl, 3a,4,5,6,7,7a-hexahydro-1H-benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-1H-indolyl, 1,2,3,4-tetrahydroquinolinyl, and decahydro-1H-cycloocta[b]pyrrolyl.
[0087]
[0059] Non-limiting examples of heteroaryls include: i) heteroaryl rings comprising a single ring, non-limiting examples of which include 1,2,3,4-tetrazolyl, [1,2,3]triazolyl, [1,2,4]triazolyl, triazinyl, thiazolyl, 1H-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) heteroaryl rings comprising two or more fused rings, one of which is a heteroaryl ring, non-limiting examples of which include 7H-prinyl, 9H-prinyl, 6-amino-9H-prinyl, 5H-pyrrolo[3,2-d]pyrimidinyl, 7H-pyrrolo[2,3-d]pyrimidinyl, pyrido[2,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1-H-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxyquinolinyl, and isoquinolinyl.
[0088]
[0060] An amine is an NH2 group. An alkylamine is an amine substituted with one or more alkyl groups. An arylamine is an amine substituted with one or more alkyl groups. A heterocyclylamine is an amine substituted with one or more heterocyclic groups. A heteroarylamine is an amine substituted with one or more heteroaryl groups.
[0089]
[0061] In some embodiments, the compound exists in a population of tautomers. All such tautomers are contemplated herein as part of the present disclosure.
[0090]
[0062] Any of the compounds herein can be purified. The compounds herein can be purified to be at least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, and at least 22% pure. , at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 41% pure, at least 42% pure, at least 43% pure, at least 44% pure , at least 45% pure, at least 46% pure, at least 47% pure, at least 48% pure, at least 49% pure, at least 50% pure, at least 51% pure, at least 52% pure, at least 53% pure, at least 54% pure, at least 55% pure, at least 56% pure, at least 57% pure, at least 58% pure, at least 59% pure, at least 60% pure, at least 61% pure, at least 62% pure, at least 63% pure, at least 64% pure, at least 65% pure, at least 66% pure , at least 67% pure, at least 68% pure, at least 69% pure, at least 70% pure, at least 71% pure, at least 72% pure, at least 73% pure, at least 74% pure, at least 75% pure, at least 76% pure, at least 77% pure, at least 78% pure, at least 79% pure, at least 80% pure, at least 81% pure, at least 82% pure, at least 83% pure, at least 84% pure, at least 85% pure, at least 86% pure, at least 87% pure, at least 88% pure,It may be at least 89% pure, at least 90% pure, at least 91% pure, at least 92% pure, at least 93% pure, at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.1% pure, at least 99.2% pure, at least 99.3% pure, at least 99.4% pure, at least 99.5% pure, at least 99.6% pure, at least 99.7% pure, at least 99.8% pure, or at least 99.9% pure.
[0091]
[0063] After preparation, the compounds of the present disclosure can be isolated and purified to obtain compositions containing the compound or a salt thereof in an amount by mass of at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100%. Pharmaceutically acceptable salts
[0064] Any of the compounds herein may be provided as pharmaceutically acceptable salts. Pharmaceutically acceptable salts include, for example, acid-addition salts and base-addition salts. The acid added to the compound to form an acid-addition salt may be an organic acid or an inorganic acid. The base added to the compound to form a base-addition salt may be an organic base or an inorganic base. In some embodiments, the pharmaceutically acceptable salt is a metal salt.
[0092]
[0065] Metal salts may arise from the addition of an inorganic base to the compounds of the present disclosure. The inorganic base consists of a metal cation paired with a basic counterion, such as hydroxide, carbonic acid, bicarbonate, or phosphoric acid. The metal may be an alkali metal, an alkaline earth metal, a transition metal, or a typical metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
[0093]
[0066] In some embodiments, the metal salt is a lithium salt, sodium salt, potassium salt, cesium salt, cerium salt, magnesium salt, manganese salt, iron salt, calcium salt, strontium salt, cobalt salt, titanium salt, aluminum salt, copper salt, cadmium salt, or zinc salt.
[0094]
[0067] Ammonium salts may result from the addition of ammonia or an organic amine to the compounds of the present disclosure. In some embodiments, the organic amine is triethylamine, diisopropylamine, ethanolamine, diethanolamine, triethanolamine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrazole, imidazole, or pyrazine.
[0095]
[0068] In some embodiments, the ammonium salt is triethylamine salt, trimethylamine salt, diisopropylamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, morpholine salt, N-methylmorpholine salt, piperidine salt, N-methylpiperidine salt, N-ethylpiperidine salt, dibenzylamine salt, piperazine salt, pyridine salt, pyrazole salt, pyridazine salt, pyrimidine salt, imidazole salt, or pyrazine salt.
[0096]
[0069] Acid addition salts may result from the addition of an acid to the compounds of the present disclosure. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrite, sulfuric acid, sulfurous acid, phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisic acid, gluconic acid, glucuronic acid, saccharic acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.
[0097]
[0070] In some embodiments, the salt is hydrochloride, hydrobromide, hydroiodide, nitrate, nitrite, sulfate, sulfite, phosphate, isonicotinate, lactate, salicylate, tartrate, ascorbate, gentisinate, gluconate, glucuronate, saccharinate, formate, benzoate, glutamate, pantothenate, acetate, propionate, butyrate, fumarate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, citrate, oxalate, or maleate.
[0098]
[0071] In some embodiments, one or more compounds of the present disclosure are in the form of protonated salts on a nitrogen atom, including salts formed with organic and inorganic anions and cations discussed herein. Non-limiting examples of such acids include hydrochloric acid, hydrofluoric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, acetic acid, succinic acid, citric acid, lactic acid, maleic acid, fumaric acid, palmitic acid, cholic acid, pamoic acid, mucinic acid, D-glutamic acid, D-camphoric acid, glutaric acid, phthalic acid, tartaric acid, lauric acid, stearic acid, salicylic acid (salicyclic), methanesulfonic acid, benzenesulfonic acid, sorbic acid, picric acid, benzoic acid, and cinnamic acid. therapeutic use
[0072] In some embodiments, the present disclosure provides compounds that can treat ryanodine receptor (RyR) related conditions, disorders, and diseases.
[0099]
[0073] In some embodiments, the Disclosure provides compounds that are RyR modulators, for example, Rycal compounds. Rycal compounds are small molecules that can bind to, for example, a leaky RyR subunit, restore calstabine binding, and repair channel leakage. In some embodiments, Rycal binds to a leaky RyR channel, restores calstabine binding, and repairs channel leakage without blocking the RyR channel. In some embodiments, Rycal compounds can repair leakage of RyR channels, for example, RyR1, RyR2, and / or RyR3 channels. In some embodiments, compositions of the Disclosure enhance the association and / or inhibit the dissociation of RyR and calstabine (e.g., RyR1 and calstabine 1, RyR2 and calstabine 2, and RyR3 and calstabine 1).
[0100]
[0074] Non-limiting examples of conditions, disorders, and diseases associated with RyR include disorders and diseases that can be treated and / or prevented by modulating RyR, such as cardiac disorders or diseases, musculoskeletal disorders or diseases, cancer-related muscle weakness, malignant hyperthermia, and diabetes. The compounds herein can also reduce the likelihood of such conditions developing.
[0101]
[0075] In some embodiments, the Disclosure provides a method for treating a medical condition or reducing the likelihood of its occurrence by administering a therapeutically effective amount of a compound disclosed herein, for example, a compound of formula (I), formula (I'), formula (II), formula (III), or formula (IV) as described herein, or a pharmaceutically acceptable salt thereof, to a subject in need. In some embodiments, the compound is administered in a pharmaceutical composition. In some embodiments, the compound is a unit dosage form. In some embodiments, the unit dosage form is a solid dosage form. In some embodiments, the pharmaceutical composition is a unit dosage form suitable for oral administration.
[0102]
[0076] In some embodiments, the present disclosure provides compounds, for example, compounds of formula (I), formula (I'), formula (II), formula (III), or formula (IV) as described herein, or pharmaceutically acceptable salts thereof, for use in methods of treating a medical condition or reducing the likelihood of its occurrence.
[0103]
[0077] In some embodiments, the present disclosure provides compounds, for example, compounds of formula (I), formula (I'), formula (II), formula (III), or formula (IV) as described herein, or pharmaceutically acceptable salts thereof, for use in the manufacture of pharmaceuticals.
[0104]
[0078] In some embodiments, the medical condition, disorder, or disease is related to the abnormal function of RyR1. In some embodiments, the medical condition, disorder, or disease is related to the abnormal function of RyR2. In some embodiments, the medical condition, disorder, or disease is related to the abnormal function of RyR3.
[0105]
[0079] In some embodiments, the present disclosure provides a method for modulating the binding of RyR and calstabine in a subject, comprising the step of administering to the subject an amount of a compound effective in modulating the amount of RyR-bound calstabine, for example, a compound of formula (I), formula (I'), formula (II), formula (III), or formula (IV) described herein, or a salt thereof. In some embodiments, the compound is used in a dose sufficient to restore or enhance the binding of calstabine 2 to RyR2. In other embodiments, the compound is used in a dose sufficient to restore or enhance the binding of calstabine 2 to RyR2. In some embodiments, the compound is used in a dose sufficient to restore or enhance the binding of calstabine 1 to RyR1. In other embodiments, the compound is used in a dose sufficient to restore or enhance the binding of calstabine 1 to RyR1.
[0106]
[0080] The methods of the present disclosure can be carried out in vitro (e.g., in cultured cells or tissues) or in vivo (e.g., in non-human animals or in humans). Lyanodine receptor: Excitation-contraction coupling (ECC) process
[0081] The sarcoplasmic reticulum (SR) is particularly rich in special intracellular calcium (Ca 2+ It is an intracellular structure that functions as a storage area. The ryanodine receptor (RyR) is a channel located in the sarcoplasmic receptacle (SR) that opens and closes, allowing Ca to flow from the SR to the intracellular cytoplasm. 2+ It controls the release of Ca from SR to the cytoplasm. 2+ The release of cytoplasmic Ca 2+ The concentration is increased. The probability of RyR opening is that a given RyR opens at any given moment, and therefore Ca from SR to the cytoplasm. 2+ This refers to the possibility of releasing something.
[0107]
[0082] RyR is a major Ca on the SR involved in excitation-contraction coupling (ECC) in striated muscle. 2+ It is a release channel. Of the three known RyR isoforms (RyR1, RyR2, and RyR3), RyR1 is widely expressed and is the main isoform expressed in mammalian skeletal muscle. RyR2 is also widely expressed and is the main form found in cardiac muscle. RyR3 expression is low in adult skeletal muscle. RyR subtypes exhibit a high degree of structural and functional homology. Subtypes are related to proteins such as kinases, phosphatases, phosphodiesterases, and other regulatory subunits. 2+ It forms a large sarcoplasmic reticulum membrane complex consisting of four monomers that make up the release channel.
[0108]
[0083] Ca from SR 2+ Release is regulated by several RyR-binding proteins. Ca 2+Calmodulin, a key mediator in signal transduction, exerts both positive and negative effects on RyR opening probability. Calstabin 1 (FKBP12) and calstabin 2 (FKBP12.6) stabilize the closed state of RyR1 and RyR2, respectively. Calstabin 1 primarily associates with skeletal muscle RyR1, while cardiac muscle RyR2 has the highest affinity for calstabin 2.
[0109]
[0084] Mutations in RyR1 or RyR2 may cause a decrease in the binding of calstabine 1 and calstabine 2, respectively. Stress-induced post-translational modifications of RyR, including PKA phosphorylation, oxidation, and nitrosylation, may also cause a decrease in the binding of calstabine to the RyR channel. Genetic mutations and / or stress-induced post-translational modifications of the channel may cause dissociation of calstabine from RyR, making the channel a leaky channel. Dissociation of calstabine may result in a leaky channel that exhibits a pathological increase in opening probability at rest. Ca of SR 2+ The leakage is from SR Ca 2+ This results in a decrease in content and makes Ca available for release. 2+ This leads to a decrease in intracellular calcium, resulting in weaker muscle contraction. Intracellular calcium leakage can lead to different pathological consequences depending on which tissues are involved. Disorders of ryanodine receptors and the central nervous system
[0085] In some embodiments, the pharmaceutical compositions described herein are administered to subjects in need. In some embodiments, subjects in need have a medical condition or disease. In some embodiments, the pharmaceutical compositions described herein are administered to treat subjects in need who have a medical condition or disease, wherein the pharmaceutical compositions described herein alleviate one or more symptoms of the medical condition or disease.
[0110]
[0086] In some embodiments, the RyR-related condition is a central nervous system (CNS) disorder or disease involving ryanodine receptor 1 (RyR1). In some embodiments, the RyR-related condition is a central nervous system (CNS) disorder or disease involving ryanodine receptor 2 (RyR2). In some embodiments, the RyR-related condition is a central nervous system (CNS) disorder or disease involving ryanodine receptor 3 (RyR3). In some embodiments, the condition is a condition, disorder, or disease of the peripheral central nervous system. In some embodiments, the condition is a neurological condition, disorder, or disease. In some embodiments, the condition is a neurodegenerative disease. In some embodiments, the condition is a cognitive impairment. In some embodiments, the compounds of the Disclosure are useful for improving cognitive function. In some embodiments, the compounds of the Disclosure are useful for treating cognitive impairment. In some embodiments, the compounds of the Disclosure are useful for slowing the progression of cognitive impairment. In some embodiments, the compounds of this disclosure are useful in reducing the likelihood of cognitive impairment occurring.
[0111]
[0087] In some embodiments, the present disclosure relates to a method for treating or reducing the likelihood of the occurrence of neurological conditions, disorders, and diseases by administering to a subject in need of such a pharmaceutical composition, for example, a compound of formula (I), a compound of formula (I'), a compound of formula (II), a compound of formula (III), a compound of formula (IV), or a pharmaceutically acceptable salt thereof.
[0112]
[0088] In some embodiments, the present disclosure relates to the use of the compounds described herein, for example, the compound of formula (I), the compound of formula (I'), the compound of formula (II), the compound of formula (III), the compound of formula (IV), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising such compounds, for treating or reducing the likelihood of the occurrence of neurological conditions, disorders, and diseases.
[0113]
[0089] In another embodiment, the present disclosure relates to pharmaceutical compositions comprising the compounds described herein, for example, the compound of formula (I), the compound of formula (I'), the compound of formula (II), the compound of formula (III), the compound of formula (IV), or pharmaceutically acceptable salts thereof, for use in the treatment or reduction of the likelihood of the occurrence of neurological conditions, disorders, and diseases.
[0114]
[0090] In some embodiments, medical conditions, disorders, and diseases that can be treated or prevented by the compounds of the present disclosure include Alzheimer's disease, post-traumatic stress disorder (PTSD), Huntington's disease, neurological disorders, paroxysmal disorders, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinocerebellar ataxia, and Parkinson's disease.
[0115]
[0091] In some embodiments, the compounds of the present disclosure are useful for treating movement disorders. Non-limiting examples of movement disorders include ataxia, dystonia, chorea, Huntington's disease, functional movement disorders, multiple system atrophy, Parkinson's disease, parkinsonism, movement disorders due to Alzheimer's disease, progressive supranuclear palsy, restless limb syndrome, tardive dyskinesia, Tourette's syndrome, tremor, and Wilson's disease.
[0116]
[0092] In some embodiments, the movement disorder is or is characterized by tremor. Non-limiting examples of tremor include essential tremor, parkinsonist tremor, dystonic tremor, cerebellar tremor, psychogenic tremor, orthostatic tremor, and physiological tremor.
[0117]
[0093] In some embodiments, the motor impairment is essential tremor. Essential tremor is a tremor that primarily appears in both upper limbs and rarely in other areas such as the head, neck, vocal cords, or lower limbs. Essential tremor is one of the most common motor impairments and tends to worsen with age. Characteristically, essential tremor is more pronounced when attempting to use the upper limbs than when at rest. As a result, difficulty with handwriting or drawing is often noticeable.
[0118]
[0094] Other examples of neurodegenerative diseases include Parkinsonian disease, multiple sclerosis, autoimmune disorders, Pick's disease, diffuse Lewy body disease, progressive supranuclear palsy (Steel-Richardson syndrome), multiple system degeneration (Shy-Drager syndrome), motor neuron disease, amyotrophic lateral sclerosis, degenerative ataxia, corticobasal degeneration, ALS-Parkinson-dementia complex in Guam, subacute sclerosing panencephalitis, synucleinopathies, primary progressive aphasia, striatonigral degeneration, Machado-Joseph disease / spinocerebellar ataxia type 3 and olivopontocerebellar degeneration, Gilles de la Tourette disease, bulbar palsy and pseudobulbar palsy, spinal muscular atrophy and bulbar spinal muscular atrophy (Kennedy disease), primary lateral sclerosis, familial spastic paraplegia, Werdnig-Hoffmann disease, Kugelberg-Welander disease, and Tay-Sachs disease. Diseases include Sandhoff's disease, familial spasticity, Wohlfahrt-Kugelberg-Welander disease, spastic paraplegia, progressive multifocal leukoencephalopathy, prion diseases such as Creutzfeldt-Jakob disease, Gerstmann-Streusler-Scheinker disease, Kuru disease, and fatal familial insomnia.
[0119]
[0095] Neurodegenerative diseases also include ischemic stroke and hemorrhagic stroke, spinal cord injury, brain injury, schizophrenia, autism, ataxia, amyotrophic lateral sclerosis, Lou Gehrig's disease, Lyme disease, meningitis, migraine, motor neuron disease, pain, brain injury, brain dysfunction, spinal cord injury, peripheral nervous system disorders, cranial nerve disorders, autonomic nervous system disorders, sleep disorders, headaches, back pain and neck pain, neuropathic pain, dementia, delirium and dementia dizziness and vertigo, stupor and coma, head injury, stroke, nervous system tumors, brain or spinal cord infections, prion diseases, depression, and drug addiction.
[0120]
[0096] Dementia refers to a decline in cognitive function beyond what is expected with normal aging, resulting from injury or disease of the brain or central nervous system. Dementia typically affects cognitive functions such as learning, memory, attention, language ability, and problem-solving ability. Types and causes of dementia include Alzheimer's disease, vascular dementia (also known as multiple stroke dementia), Binswanger's disease, Lewy body dementia (DLB), persistent alcoholic dementia, frontotemporal lobar degeneration (FTLD), Pick's disease, frontotemporal dementia (or fronto variant FTLD), semantic dementia (or temporal variant FTLD), progressive non-fluent aphasia, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, and AIDS-dementia complex.
[0121]
[0097] Amyotrophic lateral sclerosis, or ALS, is a progressive neurodegenerative disease that affects upper motor neurons (motor neurons in the brain) and / or lower motor neurons (motor neurons in the spinal cord), leading to motor neuron death. Non-limited examples of ALS include classical ALS (typically affecting both lower and upper motor neurons), primary lateral sclerosis (PLS, typically affecting only upper motor neurons), progressive bulbar palsy (PBP or Bulbar Onset, typically a version of ALS that begins with difficulty swallowing, chewing, and speaking), progressive muscular atrophy (PMA, typically affecting only lower motor neurons), and familial ALS (a hereditary version of ALS).
[0122]
[0098] Multiple sclerosis, or MS, is a progressive neurodegenerative disease that results in the destruction of myelin, the membrane covering nerve cells, particularly those in the brain and spinal cord. Non-limited examples of multiple sclerosis include relapsing-remitting multiple sclerosis (RRMS), typically characterized by partial or complete recovery after an attack (also called an exacerbation, relapse, or flare-up), secondary progressive multiple sclerosis (SPMS), generally characterized by fewer relapses and increasing impairment and symptoms, and primary progressive multiple sclerosis (PPMS), generally characterized by progression of symptoms and impairment without remission.
[0123]
[0099] Alzheimer's disease, or AD, is a progressive neurodegenerative disorder characterized by dementia, and is defined by the American Psychiatric Association (DSM-IV) as the manifestation of multiple cognitive impairments, including memory impairment.
[0124]
[0100] Parkinson's disease is a neurodegenerative disease. Many of the signs and symptoms associated with Parkinson's disease may, in some cases, precede typical Parkinson's disease by many years. The involvement of the substantia nigra, which underlies the major motor features of the disease, occurs when the disease has progressed sufficiently at a neuropathological level. The motor features of Parkinson's disease are characterized by muscle rigidity, tremors, gait and postural abnormalities, slowness of movement (bradykinesia), and, in extreme cases, loss of movement (akinesia). The main symptoms are usually the result of reduced stimulation of the motor cortex and other areas of the brain by the basal ganglia, caused by insufficient formation and action of dopamine produced by dopaminergic neurons in the brain. The motor features of Parkinson's disease are only one component of a much broader disorder that causes many non-motor signs and symptoms, including olfactory dysfunction, REM sleep behavior disorder (RBD), constipation, depression, and cognitive impairment. Many of these signs and symptoms may precede the motor symptoms by several years to more than 10 years.
[0125]
[0101] Parkinsonian disorders: Several other conditions exhibit features of Parkinson's disease and are interchangeably called parkinsonian disorders, secondary parkinsonism, parkinsonian syndromes, or atypical parkinsonism. These neurological syndromes may be characterized by tremors, hypokinesia, rigidity, and postural instability. Several etiologies, including some toxins, metabolic disorders, and non-PD neurological conditions, can cause similar symptoms. Common causes include medications, primarily neuroleptic antipsychotics, especially phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupentixol and zuclopentixol), and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely as a side effect of antidepressants. Other causes include, but are not limited to, olivopontocerebellar degeneration; progressive supranuclear palsy; corticobasal degeneration; temporo-frontal dementia; drug-induced effects by antipsychotics, prochlorperazine, or metoclopramide; carbon monoxide poisoning; head trauma; and Huntington's disease parkinsonism. In some cases, alpha-synucleinopathy may cause parkinsoniform disease, secondary parkinsonism, parkinsonian syndrome, or atypical parkinsonism. In some embodiments, the methods described herein are used to diagnose parkinsoniform disease, secondary parkinsonism, and parkinsonian syndrome. Cognitive impairment
[0102] In some embodiments, the compounds of the Disclosure are useful for treating cognitive impairment. In some embodiments, the Disclosure relates to a method for treating cognitive impairment, reducing the likelihood of its occurrence, or improving cognitive function by administering a certain amount of a compound described herein, for example, a compound of formula (I), a compound of formula (I-A), a compound of formula (II), or a compound of formula (III), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing such a compound, to a subject in need.
[0126]
[0103] In some embodiments, the present disclosure relates to the use of the compounds described herein, for example, the compounds of formula (I), the compounds of formulas (I-A), the compounds of formula (II), or the compounds of formula (III), or pharmaceutically acceptable salts thereof, or pharmaceutical compositions comprising such compounds, for treating cognitive impairment or reducing the likelihood thereof, or for improving cognitive function.
[0127]
[0104] In some embodiments, the present disclosure relates to a pharmaceutical composition comprising the compounds described herein, for example, the compound of formula (I), the compounds of formulas (I-A), the compound of formula (II), or the compound of formula (III), or pharmaceutically acceptable salts thereof, for use in treating cognitive impairment or reducing the likelihood of its occurrence, or for improving cognitive function.
[0128]
[0105] In some embodiments, cognitive impairment is related to stress-related cognitive impairment, age-related cognitive impairment, or a combination thereof. In some embodiments, cognitive impairment is related to a disease. Non-limiting examples of diseases involved in cognitive impairment include post-traumatic stress disorder, attention deficit hyperactivity disorder, autism spectrum disorder, generalized anxiety disorder, obsessive-compulsive disorder, schizophrenia, bipolar disorder, Parkinson's disease, and major depressive disorder.
[0129]
[0106] In some embodiments, the compounds of the present disclosure improve cognitive functions, such as short-term memory, long-term memory, attention, learning, and any combination thereof. Lyanodine receptor 2 and heart disease
[0107] In some embodiments, RyR-related conditions are cardiac disorders or diseases involving ryanodine receptor 2 (RyR2). The RyR2 channel is required for cardiomyocyte ECC by releasing Ca from the sarcoplasmic reticulum (SR) of cardiomyocytes. 2+By regulating its release, it plays a major role in the handling of intracellular calcium. The RyR2 channel is a macromolecular complex that includes four identical RyR2 subunits, each bound to one calstabin 2 (FKBP12.6), as well as other interacting proteins such as phosphatases and kinases. The binding of calstabin 2 stabilizes the channel in a closed state during cardiac rest (diastole), thereby preventing diastolic calcium leakage from the SR, and functionally links the cluster of RyR2 channels during excitation-contraction coupling, enabling synchronized opening.
[0130]
[0108] Phosphorylation of RyR2 by protein kinase A (PKA) is an important part of the fight-or-flight response. Phosphorylation is the release of Ca in response to a given trigger. 2+ Increasing the amount of increases the cardiac EC coupling. In this process, muscle contraction is strengthened and exercise capacity is improved. This signaling pathway provides a mechanism by which the sympathetic nervous system (SNS) is activated in response to stress, increasing cardiac output. Phosphorylation of RyR2 by PKA increases the sensitivity of the channel to calcium-dependent activation. Increased sensitivity leads to an increased probability of opening, and increased calcium release from SR into the intracellular cytoplasm.
[0131]
[0109] Heart failure (HF) is characterized by a persistent adrenaline hyperphosphatemia with chronically elevated serum catecholamine levels. One consequence of this chronic adrenaline hyperphosphatemia is persistent PKA hyperphosphorylation of RyR2, in which 3-4 of the 4 Ser2808s in each homotetrameric RyR2 channel are chronically phosphorylated. Chronic PKA hyperphosphorylation of RyR2 is associated with the depletion of the channel stabilizing subunit calstabin 2 from the RyR2 channel macromolecular complex. Depletion of calstabin 2 leads to the depletion of diastolic SR Ca from the RyR complex. 2+ This causes leakage and contributes to a decrease in contractile force. Due to the activation of inward depolarization current, this diastolic SR Ca 2+Leakage is also associated with fatal cardiac arrhythmias. Mice engineered with RyR2 lacking the PKA phosphorylation site (RyR-S2808A) are protected from HF progression after myocardial infarction (MI). Furthermore, chronic PKA hyperphosphorylation of RyR2 in HF is associated with remodeling of the RyR2 macromolecular complex. Remodeling involves depletion of phosphatases PP1 and PP2a from the RyR2 complex (reducing dephosphorylation of Ser2808) as well as depletion of cAMP-specific phosphodiesterase type IV (PDE4D3). Depletion of PDE4D3 from the RyR2 complex leads to a persistent increase in local cAMP levels. Therefore, diastolic SR Ca 2+ Leakage contributes to HF progression and arrhythmias. Further post-translational modifications of RyR channels (oxidation and nitrosylation) further promote leakage.
[0132]
[0110] RyR leakage is associated with various cardiac disorders, conditions, and diseases. In some embodiments, the cardiac disorder or disease is heart failure. In some embodiments, the cardiac disorder or disease is myocardial infarction (MI). In some embodiments, heart failure is congestive heart failure. In some embodiments, heart failure is chronic heart failure. In some embodiments, heart failure is systolic heart failure. In some embodiments, heart failure is diastolic heart failure. In some embodiments, heart failure is acute decompensated heart failure. In some embodiments, heart failure is heart failure with reduced or maintained ejection fraction. In some embodiments, heart failure is acute heart failure, for example, for maintaining cardiac function after myocardial infarction or cardiomyopathy.
[0133]
[0111] In some embodiments, cardiac disorders or diseases include cardiac ischemia / reperfusion (I / R) injury. I / R injury may occur after coronary angioplasty or thrombolysis for the treatment of myocardial infarction (MI), or during / after cardiac bypass surgery or heart transplantation.
[0134]
[0112] In some embodiments, the cardiac disorder or disease is characterized by an irregular heartbeat or arrhythmia. In some embodiments, the cardiac disorder or disease is catecholamine-induced polymorphic ventricular tachycardia (CPTV). In some embodiments, the cardiac disorder or disease is or is characterized by an atrial arrhythmia. In some embodiments, the cardiac disorder or disease is or is characterized by a ventricular arrhythmia. In some embodiments, the cardiac disorder or disease is or is characterized by atrial fibrillation. In some embodiments, the cardiac disorder or disease is or is characterized by ventricular fibrillation. In some embodiments, the cardiac disorder or disease is or is characterized by an atrial tachyarrhythmia. In some embodiments, the cardiac disorder or disease is or is characterized by a ventricular tachyarrhythmia. In some embodiments, the cardiac disorder or disease is or is characterized by atrial tachycardia. In some embodiments, the cardiac disorder or disease is or is characterized by ventricular tachycardia. In some embodiments, the cardiac disorder or disease is or is characterized by sick sinus syndrome. In some embodiments, the cardiac disorder or disease is or is characterized by sudden infant death syndrome (SDIS). In some embodiments, the cardiac disorder or disease is or is characterized by sudden death of unknown cause (SUD).
[0135]
[0113] In some embodiments, the cardiac disorder or disease is catecholamine-induced polymorphic ventricular tachycardia (CPVT). CPVT is one of the most deadly hereditary arrhythmogenic disorders. CPVT is characterized by adrenaline-mediated ventricular arrhythmias that occur in the absence of structural cardiac disease and are associated with a high incidence of sudden cardiac death (SCD). Patients typically exhibit stress-induced syncope in the 10th or 20th year of life. CPVT is associated with mutations in two genes that encode proteins related to the sarcoplasmic reticulum (SR) of cardiomyocytes. The most frequently observed form is CPVT1, an autosomal dominant type resulting from a mutation in RyR2. This type encodes an intracellular SR calcium release channel. RyR2 mutations associated with CPVT result in a leaky RyR2 channel due to reduced binding of the calstabin 2 (FKBP12.6) subunit, which stabilizes the closed state of the channel. Mice heterozygous for the RyR2 R2474S mutation (which occurs in human CPVT1) (RyR2-R2474S) may exhibit exercise-induced ventricular arrhythmias and sudden cardiac death. Treatment with Rycal, which enhances the binding of calstabin 2 to the mutated RyR2-R2474S channel, can inhibit channel leakage and prevent cardiac arrhythmias. Lyanodine receptor 1 and musculoskeletal diseases
[0114] In some embodiments, RyR-related conditions are musculoskeletal disorders or diseases involving ryanodine receptor 1 (RyR1). The RyR1 macromolecular complex consists of a tetramer of 560 kDa RyR1 subunits that forms a scaffold for proteins that regulate channel function, including PKA and phosphodiesterase 4D3 (PDE4D3), protein phosphatase 1 (PP1), and calstabine 1. A kinase anchor protein (mAKAP) leads PKA and PDE4D3 to RyR1, while spinophilin leads PP1 to the channel. The catalytic and regulatory subunits of PKA, PP1, and PDE4D3 regulate the phosphorylation of RyR1 at Ser2843 (Ser2844 in mice) via PKA. Phosphorylation of RyR1 at Ser2844 via PKA leads to cytoplasmic Ca 2+This increases the channel's sensitivity to RyR1, decreases the binding affinity of calstabin 1 to RyR1, and destabilizes the channel's closed state.
[0136]
[0115] The calstabine 1 concentration in skeletal muscle can be approximately 200 nM. PKA phosphorylation of RyR1 can reduce the binding affinity of calstabine 1 to RyR1 from approximately 100-200 nM to over 600 nM. Therefore, under physiological conditions, the decrease in the binding affinity of calstabine 1 to RyR1 resulting from PKA phosphorylation of RyR1 at Ser2843 is sufficient to significantly reduce the amount of calstabine 1 present in the RyR1 complex. Chronic PKA hyperphosphorylation of RyR1 at Ser2843 leads to leaky channels (i.e., channels that tend to open in a resting state), which contribute to skeletal muscle dysfunction associated with persistent adrenaline hyperactivity, as seen in individuals with heart failure.
[0137]
[0116] Furthermore, post-translational modifications other than phosphorylation, such as nitrosylation (S-nitrosylation) of free sulfhydryl groups on cysteine residues and control of RyR1 by channel oxidation, can enhance RyR1 channel activity. S-nitrosylation and oxidation of RyR1 can reduce the binding of carstabin 1 to RyR1, respectively.
[0138]
[0117] In some embodiments, the musculoskeletal disorder or disease is a congenital myopathy or congenital muscular dystrophy (CMD). Congenital muscular dystrophy is present at birth. CMDs are classified based on genetic mutations: 1) genes encoding structural proteins of the basement membrane or extracellular matrix of skeletal muscle fibers, 2) genes encoding putative or demonstrated glycosyltransferases that sequentially affect the glycosylation of dystroglycans, which are outer membrane proteins of the basement membrane, and 3) others. Non-limiting examples of CMD include RYR1-associated myopathy (RYR1-RM), laminin-α2-deficient CMD (MDC1A), Ulrich CMG (UCMD1, 2, and 3), Walker-Warburg syndrome (WWS), muscle-ophthalm-brain disease (MEB), Fukuyama-type CMD (FCMD), CMD with secondary laminin deficiency 1 (MDC1B), CMD with secondary laminin deficiency 2 (MDC1C), CMD with intellectual disability and macrolevary syndrome (MDC1D), and rigid spina with muscular dystrophy type 1 (RSMD1).
[0139]
[0118] In some embodiments, the musculoskeletal disorder is RYR1-related congenital myopathy (RYR1-RM). RYR1-RM includes a group of rare neuromuscular disorders. Affected individuals generally exhibit delayed motor milestones, muscle weakness, impaired gait, and, in severe cases, scoliosis, ophthalmoplegia, and respiratory distress, all due to skeletal muscle weakness. The main calcium component of skeletal muscle is Ca 2+ Causative variants of RYR1, which encodes the release channel, have different effects on the RyR1 channel. These variants generally affect the normal Ca between the sarcoplasmic reticulum (SR) and myocyte cytoplasm. 2+ This obstructs the flow of calcium, which normally leads to excess calcium entering the cytoplasm. 2+ Causes leakage. Persistent Ca 2+ Leakage is necessary for ECC. 2+ It reduces chronic SR Ca 2+ Leakage causes mitochondrial calcium overload, which impairs mitochondrial function and manifests as oxidative overload and decreased ATP production. SR Ca 2+Leakage can also activate calpain, a calcium-activated protease, which can cause cell damage. Next, oxidative stress can lead to the oxidation and nitrosylation of the channel of RyR1 Ca 2+ This could further contribute to leakage.
[0140]
[0119] In some embodiments, the musculoskeletal disorder or disease is a muscular dystrophy. Non-limiting examples of muscular dystrophy include Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), limb-girdle muscular dystrophy (LGMD), facioscapulohumeral dystrophy, myotonic muscular dystrophy, congenital muscular dystrophy (CMD), distal muscular dystrophy, Emery-Dreyfus muscular dystrophy, and oculopharyngeal muscular dystrophy.
[0141]
[0120] Duchenne muscular dystrophy (DMD) is one of the most common fatal genetic disorders in childhood. Mutations in dystrophin associated with DMD result in the complete loss of the dystrophin protein, thereby disrupting the junction between the cytoskeleton beneath the muscle cell membrane and the extracellular matrix. This junction is essential for protecting and stabilizing the muscle from damage induced by contraction. Muscle cell membrane instability due to dystrophin mutations has a cascade effect. One of the main effects is cytoplasmic Ca 2+ This is an increase in concentration, and this is Ca 2+ This leads to the activation of the dependent protease (calpain). Another effect is increased inflammation and iNOS activity, which can cause oxidation / nitrosylation of proteins, lipids, and DNA. The myopathy of DMD is progressive and goes far beyond muscle cell membrane instability. Therefore, this pathology is consistent with muscle cell membrane instability increasing susceptibility to further damage. Excessive oxidation or nitrosylation of RyR1 interferes with the interaction of the calstabine 1-RyR1 complex, leading to RyR1 leakage and muscle weakness. Treatment with Rycal improves indicators of muscle function.
[0142]
[0121] In some embodiments, the musculoskeletal disorder or disease is cancer cachexia, i.e., cancer-related muscle weakness. In some embodiments, cancer-related muscle weakness is, for example, cancer cachexia resulting from cancer with bone metastases. Muscle weakness and muscle atrophy (cachexia) are common paraneoplastic conditions in cancer patients. These conditions cause significant fatigue and dramatically reduce the patient's quality of life. In certain cancers, such as prostate cancer and breast cancer with bone metastases, RyR1 is oxidized and induced to become leaky. Restoration of leakiness by administration of Rycal compounds improves muscle function. Non-limiting examples of cancers with cachexia that can be treated with the compounds herein include breast cancer, prostate cancer, bone cancer, pancreatic cancer, lung cancer, colon cancer, and gastrointestinal cancer. These conditions cause significant fatigue and dramatically reduce the patient's quality of life. This disclosure provides methods for treating, preventing, and reducing the likelihood of muscle weakness in cancer patients, based, for example, on the presence of a modified (e.g., oxidative state of RyR1) that induces RyR1 to become leaky. Prevention of leakage or reduction of the likelihood of its occurrence by administration of a Rycal compound can improve muscle function.
[0143]
[0122] In some embodiments, the musculoskeletal condition or disease is age-related loss of muscle mass and strength (sarcopenia). Sarcopenia contributes to increased physical disability and mortality. RyR1 in aged mice may be oxidized, cysteine nitrosylated, and calstabin 1 depleted compared to RyR1 in young (3-6 month) adult mice. Treatment of aged mice with Rycal stabilizes the binding of calstabin 1 to RyR1, reduces intracellular calcium leakage, reduces reactive oxygen species (ROS), and reduces tetanic Ca 2+ It may enhance release, muscle-specific force, and athletic performance.
[0144]
[0123] In some embodiments, the compositions of the present disclosure are useful for treating pancreatic conditions, such as diabetes mellitus. In some embodiments, the compositions of the present disclosure are useful for treating type II diabetes mellitus by reducing the likelihood of intracellular calcium leakage via leaky RyR2. This leakage causes mitochondrial calcium overload, which reduces ATP production, and this is K ATP It reduces channel activation. This reduction in channel activation prevents cell membrane depolarization. This inhibition reduces the activation of cell membrane potential-opening calcium channels, which are the main source of calcium required for insulin secretion. Pharmaceutical composition
[0124] The compounds of this disclosure may be administered as is or as pharmaceutical compositions for administration to human or animal subjects in a biocompatible form suitable for in vivo administration. Subjects may be, for example, elderly adults, adults, adolescents, pre-adolescents, children, infants, neonates, and non-human animals. In some embodiments, the subject is a patient.
[0145]
[0125] The compounds of the Disclosure are formulated into pharmaceutical compositions for administration to human subjects in a biocompatible form suitable for in vivo administration. In some embodiments, the Disclosure provides pharmaceutical compositions comprising the compounds of the Disclosure in combination with pharmaceutically acceptable excipients, diluents, and / or carriers. The pharmaceutically acceptable carrier is preferably acceptable in the sense that it is compatible with the other components of the composition and is not harmful to its recipient.
[0146]
[0126] Non-limiting examples of administration routes include oral, sublingual, buccal, parenteral, (intravenous, intramuscular, or subcutaneous), transdermal, per- or trans-cutaneous, intranasal, vaginal, rectal, ocular, and respiratory (by inhalation). In some embodiments, the compound is administered directly to the CNS, for example, by direct intralumbar injection or intraventricular infusion into the cerebrospinal fluid (CSF), or by intraventricular, intrathecal, or interstitial administration. Administration can be to the muscle of the subject, for example, the cardiac or skeletal muscle of the subject. In some embodiments, the compound is administered to the subject by targeted delivery to cardiomyocytes via a catheter inserted into the heart of the subject. In some embodiments, the compound is administered orally.
[0147]
[0127] Pharmaceutical compositions for solid oral administration include tablets, sugar-coated tablets, sublingual tablets, gastro-resistant tablets, sachets, capsules including gelatin capsules, powders, and granules. Liquid formulations for oral, nasal, buccal, or ocular administration include emulsions, solutions, suspensions, drips, syrups, and aerosols. Compounds may also be administered as suspensions or solutions via drinking water or with food.
[0148]
[0128] Non-limiting examples of pharmaceutically acceptable excipients or carriers include organic or inorganic materials used as materials in pharmaceutical formulations and incorporated as one or more of the following: fillers, diluents, binders, disintegrants, buffers (pH adjusters), colorants, emulsifiers, flavor enhancers, gelling agents, flow enhancers, surfactants (wetting agents), preservatives, solubilizers, stabilizers, suspending agents, sweeteners, isotonic agents, emulsifiers, dispersants, leavening agents, retarders, lubricants, absorbents, plasticizers, and viscosity enhancers.
[0149]
[0129] Non-limiting examples of pharmaceutically acceptable fillers / diluents include cellulose derivatives, including microcrystalline cellulose, silicified microcrystalline cellulose, carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and ethylcellulose, starch, sugars, such as mannitol, sucrose, lactose, sorbitol, dextrin (e.g., maltodextrin), amino sugars, alginic acid, sodium alginate, and water.
[0150]
[0130] Non-limiting examples of pharmaceutically acceptable binders include microcrystalline cellulose, tragacanth gum, acacia gum, gelatin, polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose, and starch.
[0151]
[0131] Non-limiting examples of pharmaceutically acceptable disintegrants include roscarmellose sodium, carboxymethyl starch sodium, and crospovidone.
[0152]
[0132] Non-limiting examples of pharmaceutically acceptable lubricants include stearates, such as magnesium stearate or zinc stearate, stearic acid, sodium stearyl fumarate, talc, glyceryl behenate, sodium lauryl sulfate, polyethylene glycol, and hydrogenated vegetable oils.
[0153]
[0133] Non-limiting examples of pharmaceutically acceptable flow enhancers include colloidal silicon dioxide, talc, tricalcium phosphate, calcium silicate, cellulose, magnesium silicate, magnesium trisilicate, starch, magnesium stearate, talc, and mineral oil. Non-limiting examples of moisture barrier agents include stearic acid.
[0154]
[0134] Non-limiting examples of pharmaceutically acceptable plasticizers include triethyl citrate.
[0155]
[0135] Non-limiting examples of pharmaceutically acceptable surfactants include sodium lauryl sulfate or polysorbate, polyvinyl alcohol (PVA), polyethylene glycol, polyoxyethylene-polyoxypropylene block copolymers known as "poloxamers," polyglycerin fatty acid esters such as decaglyceryl monolaurate and decaglyceryl monomyristate, sorbitan fatty acid esters such as sorbitan monostearate, polyoxyethylene sorbitan fatty acid esters such as polyoxyethylene sorbitan monooleate (Tween), polyethylene glycol fatty acid esters such as polyoxyethylene monostearate, polyoxyethylene alkyl ethers such as polyoxyethylene lauryl ether, polyoxyethylene castor oil, and hydrogenated castor oil such as polyoxyethylene hydrogenated castor oil.
[0156]
[0136] Non-limiting examples of pharmaceutically acceptable flavorings include sweeteners such as sucralose, synthetic flavoring oils and flavoring aromatics, natural oils, extracts from plants, leaves, flowers and fruits, and combinations thereof. Non-limiting examples of flavorings include cinnamon oil, wintergreen oil, peppermint oil, clover oil, hay oil, anise oil, eucalyptus, peppermint, vanilla, lemon oil, orange oil, grape and grapefruit oil and other citrus oils, as well as fruit essences such as apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple and apricot.
[0157]
[0137] Non-limiting examples of pharmaceutically acceptable pigments or colorants include alumina (dried aluminum hydroxide), annatto extract, calcium carbonate, canthaxanthin, caramel, β-carotene, cochineal extract, carmine, sodium potassium copper chlorophyllin (chlorophyllin-copper complex), dihydroxyacetone, bismuth oxychloride, synthetic iron oxide, ammonium ferric ferrocyanide, ferric ferrocyanide, chromium hydroxide green, chromium oxide green, guanine, mica-based pearlescent pigments, pyrophyllite, mica, toothpaste, talc, titanium dioxide, aluminum powder, bronze powder, copper powder, and zinc oxide.
[0158]
[0138] Non-limiting examples of buffers or pH adjusters include acidic buffers such as short-chain fatty acids, citric acid, acetic acid, hydrochloric acid, sulfuric acid, and fumaric acid, as well as basic buffers such as Tris, sodium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, and magnesium hydroxide.
[0159]
[0139] Non-limiting examples of tonicity enhancing agents include ionic and non-ionic agents, such as alkali metal or alkaline earth metal halides, urea, glycerol, sorbitol, mannitol, propylene glycol, and dextrose.
[0160]
[0140] Non-limiting examples of wetting agents include glycerin, cetyl alcohol, and glycerol monostearate.
[0161]
[0141] Non-limiting examples of preservatives include benzalkonium chloride, benzoxonium chloride, thiomersal, phenylmercury nitrate, phenylmercury acetate, phenylmercury borate, methylparaben, propylparaben, chlorobutanol, benzyl alcohol, phenyl alcohol, chlorohexidine, and polyhexamethylene biguanide.
[0162]
[0142] Non-exclusive examples of antioxidants include sorbic acid, ascorbic acid, ascorbate, glycine, α-tocopherol, butylhydroxyanisole (BHA), and butylhydroxytoluene (BHT).
[0163]
[0143] In some embodiments, the solid dosage form is coated. In some embodiments, the solid dosage form includes a core, a sub-coating layer substantially surrounding the core, and a coating layer substantially surrounding the sub-coating layer.
[0164]
[0144] In some embodiments, the sub-coating layer comprises a swellable hydrophobic polymer layer (for example, a swellable polymer such as hydroxypropyl cellulose (HPC) or hydroxypropyl methylcellulose (HPMC)).
[0165]
[0145] In some embodiments, the coating layer includes an enteric polymer. Non-limiting examples of enteric polymers include hydroxypropyl methylcellulose acetate succinate (hypromellose acetate succinate, HPMC-AS), cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, cellulose acetate trimellitate, polyvinyl acetate phthalate, methacrylic acid / methacrylic acid ester copolymer (e.g., poly(methacrylic acid-co-methyl methacrylate), methacrylic acid / acrylic acid ester copolymer, and shellac (ester of aleuric acid).
[0166]
[0146] In some embodiments, pharmaceutically acceptable carriers or excipients are used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions for oral administration by a subject. Non-limiting examples of solvents used in oral dissolution formulations may include water, ethanol, isopropanol, saline, physiological saline, DMSO, potassium phosphate buffer, phosphate-buffered saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazine ethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC). Non-limiting examples of cosolvents used in oral dissolution formulations may include sucrose, urea, cremaphor, and potassium phosphate buffer.
[0167]
[0147] Pharmaceutical compositions for parenteral injection may include sterile solutions, dispersions, suspensions, emulsions, and sterile powders for reconstitution of injection solutions or dispersions, which may be aqueous or non-aqueous. Compounds may be combined with sterile aqueous solutions that are isotonic with the blood of the subject. Parenteral formulations may be prepared by dissolving a solid active ingredient in water containing a physiologically compatible substance such as sodium chloride or glycine, having a buffered pH suitable for physiological conditions, to produce an aqueous solution, and then sterilizing the solution. Formulations are provided in unit-dose or multi-dose containers such as sealed ampoules or vials. Formulations are delivered by any form of injection, including, but not limited to, intrafascial, intra-articular, intracranial, intradermal, intrathecal, intramuscular, intraorbital, intraperitoneal, intraspinal, intrasternal, intravascular, intravenous, intraparenchymal, subcutaneous, or sublingual, or by catheterization into the heart of the subject.
[0168]
[0148] Pharmaceutical compositions for rectal or vaginal administration may be suppositories, while those for per- or trans-cutaneous administration include powders, aerosols, creams, ointments, gels, and patches.
[0169]
[0149] For transdermal administration, the compound may be combined with a skin penetration enhancer such as propylene glycol, polyethylene glycol, isopropanol, ethanol, oleic acid, or N-methylpyrrolidone. These agents increase skin permeability, allowing the compound to penetrate through the skin into the bloodstream. The compound / enhancement composition may be further combined with a polymeric substance such as ethylcellulose, hydroxypropylcellulose, ethylene / vinyl acetate, or polyvinylpyrrolidone to provide a gel-form composition, which is dissolved in a solvent, evaporated to the desired viscosity, and applied to a backing material to provide a patch.
[0170]
[0150] The pharmaceutical formulations of this disclosure may be prepared by methods such as wet granulation, dry granulation, or direct compression.
[0171]
[0151] Pharmaceutically acceptable excipients can be present in the pharmaceutical composition in an amount of about 0.1% to about 99% by mass of the composition. For example, pharmaceutically acceptable excipients can be present in amounts of about 0.1% to about 95% by mass, about 0.11% to about 90% by mass, about 0.1% to about 85% by mass, about 0.1% to about 80% by mass, about 0.1% to about 75% by mass, about 0.1% to about 70% by mass, about 0.1% to about 65% by mass, about 0.1% to about 60% by mass, about 0.1% to about 55% by mass, and about 0.1% to about 50% by mass of the formulation. It can be present in pharmaceutical compositions in the following masses: %, approximately 0.1% to 45% by mass, approximately 0.11% to 40% by mass, approximately 0.1% to 35% by mass, approximately 0.1% to 30% by mass, approximately 0.1% to 25% by mass, approximately 0.1% to 20% by mass, approximately 0.1% to 15% by mass, approximately 0.1% to 10% by mass, approximately 0.1% to 5% by mass, and approximately 0.1% to 1% by mass.
[0172]
[0152] The excipients permitted in pharmacy are approximately 0.1% by mass, approximately 0.2% by mass, approximately 0.3% by mass, approximately 0.4% by mass, approximately 0.5% by mass, approximately 0.6% by mass, approximately 0.7% by mass, approximately 0.8% by mass, approximately 0.9% by mass, approximately 1% by mass, approximately 2% by mass, approximately 3% by mass, approximately 4% by mass, approximately 5% by mass, approximately 6% by mass, approximately 7% by mass, approximately 8% by mass, approximately 9% by mass, approximately 10% by mass, approximately 11% by mass, approximately 12% by mass, approximately 13% by mass, approximately 14% by mass, approximately 15% by mass, approximately 16% by mass, approximately 17% by mass, approximately 18% by mass, and approximately 19% by mass. %, approximately 20% by mass, approximately 21% by mass, approximately 22% by mass, approximately 23% by mass, approximately 24% by mass, approximately 25% by mass, approximately 26% by mass, approximately 27% by mass, approximately 28% by mass, approximately 29% by mass, approximately 30% by mass, approximately 31% by mass, approximately 32% by mass, approximately 33% by mass, approximately 34% by mass, approximately 35% by mass, approximately 36% by mass, approximately 37% by mass, approximately 38% by mass, approximately 39% by mass, approximately 40% by mass, approximately 41% by mass, approximately 42% by mass, approximately 43% by mass, approximately 44% by mass, approximately 45% by mass, approximately 46% by mass, approximately 47% by mass, approximately 48% by mass, approximately 49% by mass, approximately 50% by mass Approximately 51% by mass, approximately 52% by mass, approximately 53% by mass, approximately 54% by mass, approximately 55% by mass, approximately 56% by mass, approximately 57% by mass, approximately 58% by mass, approximately 59% by mass, approximately 60% by mass, approximately 61% by mass, approximately 62% by mass, approximately 63% by mass, approximately 64% by mass, approximately 65% by mass, approximately 66% by mass, approximately 67% by mass, approximately 68% by mass, approximately 69% by mass, approximately 70% by mass, approximately 71% by mass, approximately 72% by mass, approximately 73% by mass, approximately 74% by mass, approximately 75% by mass, approximately 76% by mass, approximately 77% by mass, approximately 78% by mass, approximately 79% by mass, approximately 80% by mass, approximately 81% by mass. Approximately 82% mass, approximately 83% mass, approximately 84% mass, approximately 85% mass, approximately 86% mass, approximately 87% mass, approximately 88% mass, approximately 89% mass, approximately 90% mass, approximately 91% mass, approximately 92% mass, approximately 93% mass, approximately 94% mass, approximately 95% mass, approximately 96% mass, approximately 97% mass, approximately 98% mass, approximately 99% mass, approximately 99% mass, approximately 99.1% mass, approximately 99.2% mass, approximately 99.3% mass, approximately 99.4% mass, approximately 99.5% mass, approximately 99.6% mass, approximately 99.7% mass, approximately 99.8% mass, approximately 99.9% mass. Invest in the project
[0153] Any of these compounds can be administered to (or brought into contact with) a subject in an amount effective to limit or prevent a decrease in the level of RyR-bound calstabine in the subject cells, in accordance with the methods of the present disclosure. Alternatively, the methods of the present disclosure include the step of administering an amount of the compound effective to treat or prevent a RyR-related medical condition described herein.
[0173]
[0154] In some embodiments, an appropriate amount of a compound effective in limiting or preventing a decrease in RyR-bound carstabin levels in a subject and / or treating or preventing a RyR-related condition is in the range of about 1 to about 2,000 mg per day, for example, about 10 mg per day, about 20 mg per day, about 30 mg per day, about 40 mg per day, about 50 mg per day, about 60 mg per day, about 70 mg per day, about 80 mg per day, about 90 mg per day, about 100 mg per day, about 120 mg per day, about 140 mg per day, about 160 mg per day, about 180 mg per day, about 200 mg per day, about 220 mg per day, about 240 mg per day, about 260 mg per day, about 280 mg per day mg, approximately 300 mg per day, approximately 320 mg per day, approximately 340 mg per day, approximately 360 mg per day, approximately 380 mg per day, approximately 400 mg per day, approximately 420 mg per day, approximately 440 mg per day, approximately 460 mg per day, approximately 480 mg per day, approximately 500 mg per day, approximately 600 mg per day, approximately 700 mg per day, approximately 800 mg per day, The daily dose is approximately 900 mg, 1,000 mg, 1,100 mg, 1,200 mg, 1,300 mg, 1,400 mg, 1,500 mg, 1,600 mg, 1,700 mg, 1,800 mg, 1,900 mg, or 2,000 mg.
[0174]
[0155] The compounds described herein contain approximately 1 mg to approximately 2000 mg; approximately 1 mg to approximately 1000 mg; approximately 1 mg to approximately 500 mg; approximately 5 mg to approximately 1000 mg, approximately 5 mg to approximately 500 mg, approximately 5 mg to approximately 100 mg, approximately 10 mg to approximately 50 mg, approximately 50 mg to approximately 250 mg, approximately 100 mg to approximately 200 mg, approximately 1 mg to approximately 50 mg, approximately 50 mg to approximately 100 mg, approximately 100 mg to approximately 150 mg, approximately 150 mg to approximately 200 mg, approximately 200 mg to approximately 250 mg, and approximately 250 mg to approximately 300 mg. g can exist in the range of approximately 300mg to 350mg, approximately 350mg to 400mg, approximately 400mg to 450mg, approximately 450mg to 500mg, approximately 500mg to 550mg, approximately 550mg to 600mg, approximately 600mg to 650mg, approximately 650mg to 700mg, approximately 700mg to 750mg, approximately 750mg to 800mg, approximately 800mg to 850mg, approximately 850mg to 900mg, approximately 900mg to 950mg, or approximately 950mg to 1000mg.
[0175]
[0156] The compounds described herein are present in amounts of approximately 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, and 55 mg in the composition. It can be present in amounts of 0 mg, approximately 600 mg, approximately 650 mg, approximately 700 mg, approximately 750 mg, approximately 800 mg, approximately 850 mg, approximately 900 mg, approximately 950 mg, approximately 1000 mg, approximately 1050 mg, approximately 1100 mg, approximately 1150 mg, approximately 1200 mg, approximately 1250 mg, approximately 1300 mg, approximately 1350 mg, approximately 1400 mg, approximately 1450 mg, approximately 1500 mg, approximately 1550 mg, approximately 1600 mg, approximately 1650 mg, approximately 1700 mg, approximately 1750 mg, approximately 1800 mg, approximately 1850 mg, approximately 1900 mg, approximately 1950 mg, or approximately 2000 mg.
[0176]
[0157] In some embodiments, the dose may be expressed in units of the amount of drug divided by the mass of the subject, for example, milligrams of drug per kilogram of body weight of the subject. In some embodiments, the compound may be approximately 0.01 mg / kg to approximately 2,000 mg / kg, approximately 0.01 mg / kg to approximately 1,000 mg / kg, approximately 0.01 mg / kg to approximately 100 mg / kg, approximately 0.01 mg / kg to approximately 10 mg / kg, approximately 0.01 mg / kg to approximately 5 mg / kg, approximately 0.01 mg / kg to approximately 1 mg / kg, approximately 0.01 mg / kg to approximately 0.5 mg / kg, approximately 0.01 mg / kg to approximately 0.1 mg / kg, approximately 0.01 mg / kg to approximately 0.05 mg / kg, approximately 1 mg / kg to approximately 1,000 mg / kg, approximately 1 mg / kg to approximately 500 mg / kg, approximately 1 mg It is administered in amounts ranging from approximately 250 mg / kg to 100 mg / kg, approximately 1 mg / kg to 50 mg / kg, approximately 5 mg / kg to 50 mg / kg, approximately 10 mg / kg to 20 mg / kg, approximately 10 mg / kg to 50 mg / kg, approximately 250 mg / kg to 2000 mg / kg, approximately 10 mg / kg to 800 mg / kg, approximately 50 mg / kg to 400 mg / kg, approximately 100 mg / kg to 300 mg / kg, or approximately 150 mg / kg to 200 mg / kg. In some embodiments, the compound is administered at approximately 1 mg / kg body weight, approximately 2 mg / kg body weight, approximately 5 mg / kg body weight, approximately 10 mg / kg body weight, approximately 20 mg / kg body weight, approximately 50 mg / kg body weight, approximately 100 mg / kg body weight, approximately 150 mg / kg body weight, approximately 200 mg / kg body weight, approximately 250 mg / kg body weight, approximately 300 mg / kg body weight, approximately 350 mg / kg body weight, and approximately 400 mg / kg body weight. The drug is administered at a dose of approximately 450 mg / kg, 500 mg / kg, 550 mg / kg, 600 mg / kg, 650 mg / kg, 700 mg / kg, 750 mg / kg, 800 mg / kg, 850 mg / kg, 900 mg / kg, 950 mg / kg, or 1000 mg / kg of body weight.
[0177]
[0158] In some embodiments, the dose may be expressed in units of the amount of drug per day divided by the mass of the subject, for example, milligrams of drug per kilogram of body weight per day (mg / kg / day / day). In some embodiments, the compound is administered in doses of approximately 0.01 mg / kg / day to approximately 2,000 mg / kg / day, approximately 0.01 mg / kg / day to approximately 1,000 mg / kg / day, approximately 0.01 mg / kg / day to approximately 100 mg / kg / day, approximately 0.01 mg / kg / day to approximately 10 mg / kg / day, approximately 0.01 mg / kg / day to approximately 5 mg / kg / day, approximately 0.01 mg / kg / day to approximately 1 mg / kg / day, approximately 0.01 mg / kg / day to approximately 0.5 mg / kg / day, approximately 0.01 mg / kg / day to approximately 0.1 mg / kg / day, approximately 0.01 mg / kg / day to approximately 0.05 mg / kg / day, approximately 1 mg / kg / day to approximately 1,000 mg / kg / day, approximately 1 mg / kg / day to approximately 500 mg / kg / day, and approximately 1 mg / kg / The dosage is administered in the following ranges: approximately 250 mg / kg / day, approximately 1 mg / kg / day to approximately 100 mg / kg / day, approximately 1 mg / kg / day to approximately 50 mg / kg / day, approximately 5 mg / kg / day to approximately 50 mg / kg / day, approximately 5 mg / kg / day to approximately 10 mg / kg / day, approximately 5 mg / kg / day to approximately 20 mg / kg / day, approximately 10 mg / kg / day to approximately 50 mg / kg / day, approximately 10 mg / kg / day to approximately 20 mg / kg / day, approximately 250 mg / kg / day to approximately 2000 mg / kg / day, approximately 10 mg / kg / day to approximately 800 mg / kg / day, approximately 50 mg / kg / day to approximately 400 mg / kg / day, approximately 100 mg / kg / day to approximately 300 mg / kg / day, or approximately 150 mg / kg / day to approximately 200 mg / kg / day.In some embodiments, the compound is administered at approximately 1 mg / kg of body weight / day, approximately 2 mg / kg of body weight / day, approximately 5 mg / kg of body weight / day, approximately 10 mg / kg of body weight / day, approximately 20 mg / kg of body weight / day, approximately 50 mg / kg of body weight / day, approximately 100 mg / kg of body weight / day, approximately 150 mg / kg of body weight / day, approximately 200 mg / kg of body weight / day, approximately 250 mg / kg of body weight / day, approximately 300 mg / kg of body weight / day, approximately 350 mg / kg of body weight / day, and approximately 400 mg / kg of body weight / day. The drug is administered at a dose of approximately 450 mg / kg of body weight per day, approximately 500 mg / kg of body weight per day, approximately 550 mg / kg of body weight per day, approximately 600 mg / kg of body weight per day, approximately 650 mg / kg of body weight per day, approximately 700 mg / kg of body weight per day, approximately 750 mg / kg of body weight per day, approximately 800 mg / kg of body weight per day, approximately 850 mg / kg of body weight per day, approximately 900 mg / kg of body weight per day, approximately 950 mg / kg of body weight per day, or approximately 1000 mg / kg of body weight per day.
[0178]
[0159] In some embodiments, the compounds of the present disclosure are administered in amounts sufficient to achieve a maximum plasma concentration (e.g., at steady state) in a subject ranging from about 1 ng / ml to about 5,000 ng / ml, for example, about 50 ng / ml to about 5,000 ng / ml, about 100 ng / ml to about 5,000 ng / ml, about 200 ng / ml to about 5,000 ng / ml, about 300 ng / ml to about 5,000 ng / ml, about 400 ng / ml to about 5,000 ng / ml, about 500 ng / ml to about 5,000 ng / ml, about 50 ng / ml to about 500 ng / ml, about 100 ng / ml to about 500 ng / ml, about 150 ng / ml to about 500 ng / ml, about 200 ng / ml to about 500 ng / ml, or about 250 ng / ml to about 500 ng / ml.
[0179] Synthesis method
[0160] This disclosure provides methods for preparing the compounds described herein or pharmaceutically acceptable salts thereof. In some embodiments, this disclosure provides methods for preparing the compounds of formula (I). The general route of synthesis is described in Scheme 1:
[0180] [ka]
[0181] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - R 2 These are, respectively, independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, and -C(O)NR 3 R 4 -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8 , or -C(O)C(O)OR 8 And, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5, R 6 , R 7 , and R 8 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, (X is a leaving group) or a pharmaceutically acceptable salt thereof.
[0182]
[0161] The leaving group X may be, for example, a halogen, a sulfonate (OSO2)R' in which R' is alkyl or aryl, such as OMs (mesylates), OTs (tosylates), imidazoles, phenoxy, or substituted phenoxy (for example, nitrophenoxy, C6F5O).
[0183]
[0162] In some embodiments, R of formula (I) 2 -NR 3 R 4 The compound is of formula (I'). In some embodiments, this disclosure provides a method for preparing the compound of formula (I'). A general route of synthesis is described in Scheme 2:
[0184] [ka]
[0185] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - R 3a R 3 or nitrogen protecting group, - R 4a R 4 or a nitrogen protecting group, - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - X is a leaving group as defined in Scheme 1. or a pharmaceutically acceptable salt thereof.
[0186]
[0163] In one embodiment of Scheme 2, (route [a]) an amine starting material (A) is reacted with an acylation reagent such as phosgene, triphosgene, carbonyldiimidazole, thionyl chloride, or 4-nitrophenyl chloroformate to obtain an acyl intermediate (B), which is then converted into the formula HNR 3a R 4a The amine is reacted with the intermediate (C) in the presence of a base, optionally. (Amine HNR) 3 R 4 The nitrogen protecting group is optionally included. In the alternative route [b], the amine starting material (A) is acylated into the amine XC(O)-NR 3aR 4a The mixture is reacted with the intermediate (C). If a nitrogen protecting group is present, it can be removed to obtain the compound of formula (I').
[0187]
[0164] In some embodiments, R of formula (I) 2 is a piperazinyl or a substituted piperazinyl, and the compound is a compound of formula (II). In some embodiments, this disclosure provides a method for preparing a compound of formula (II). A general synthetic route is described in Scheme 3:
[0188] [ka]
[0189] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - R 9 These are, respectively, independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8 , or hydrogen, - R 9a R 9 or a nitrogen protecting group, - Each R 10 These are independently unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -NR 3 R 4 , -OR 5 , or -SR 7 And, - m is 0, 1, 2, 3, 4, 5, 6, 7, or 8, - X is a leaving group as defined in Scheme 1. or a pharmaceutically acceptable salt thereof.
[0190]
[0165] In some embodiments of Scheme 3 (route [a]), an amine starting material (A) is reacted with an acylation reagent such as phosgene, triphosgene, carbonyldiimidazole, thionyl chloride, or 4-nitrophenyl chloroformate to obtain an acyl intermediate (B), which is then piperazine (R 9a =H), substituted piperazine (R 9a (is anything other than H), or its protective derivative (R 9aIntermediate (C') is obtained by reacting with (PG, nitrogen protecting group) in the presence of a base, optionally. In the alternative route [b], the amine starting material (A) is reacted with an acylated piperazine, a substituted acylated piperazine, or a protected acylated piperazine derivative to directly obtain intermediate (C'). If a protecting group is present, it can be removed to obtain the compound of formula (II).
[0191]
[0166] In some embodiments, the compound is of formula (II), and the synthesis route is described in scheme 3a:
[0192] [ka]
[0193] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - R 9a is a hydrogen or nitrogen protecting group, - X is a leaving group as defined in Scheme 1. or a pharmaceutically acceptable salt thereof.
[0194]
[0167] In some embodiments of scheme 3a (route [a]), an amine starting material (A) is reacted with an acylation reagent such as phosgene, triphosgene, carbonyldiimidazole, thionyl chloride, or 4-nitrophenyl chloroformate to obtain an acyl intermediate (B), which is then piperazine (R 9a =H) or its protective derivative (R 9a Intermediate (C') is obtained by reacting with (PG, nitrogen protecting group) in the presence of a base, optionally. In the alternative route [b], the amine starting material (A) is reacted with an acylated piperazine or a protected acylated piperazine derivative to directly obtain intermediate (C'). If a protecting group is present, it can be removed to obtain the compound of formula (III).
[0195] Preparation of amine starting material (A)
[0168] The amine starting material (A) can generally be prepared as shown in Scheme 4 (Method 1), Scheme 5 (Method 2), or Scheme 6 (Method 3).
[0196]
[0169] Method 1-
[0197] [ka]
[0198]
[0170] In Scheme 4, R 1a , R 1b, R 1c , and R 1d As defined above, R 3’ is alkyl or aryl, R 4’ is H or PG, where PG is a nitrogen protecting group. The starting material (D) is optionally cyclized in the presence of a base to obtain the corresponding benzothiazepanone (E), which is reduced to compound (A) or its salt, e.g., hydrochloride or hydrobromide. Any of the bases described herein can be used for this purpose. The amine group of the starting material (D) can optionally be protected, in which case the protecting group is removed before cyclization. The starting material (D) may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0199]
[0171] Method 2-
[0200] [ka]
[0201]
[0172] In Scheme 5, R 1a , R 1b , R 1c , and R 1d As defined above, X' is the leaving group defined above for X, and R 4’ is H or PG, where PG is a nitrogen protecting group. The starting material alcohol (F) is reacted with an activator to introduce group X', and then the intermediate (G) is cyclized optionally in the presence of a base to obtain the corresponding benzothiazepine derivative of formula (A) or its salt, e.g., hydrochloride or hydrobromide. Any of the bases described herein can be used for this purpose. The amine group of the starting material (G) can optionally be protected, in which case the protecting group is removed before cyclization. The starting material (F) and / or intermediate (G) may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0202]
[0173] Method 3-
[0203] [ka]
[0204]
[0174] In Scheme 6, R 1a , R 1b , R 1c , and R 1d As defined above, X and X' are the leaving groups defined above, and R 5’ is H or PG', where PG' is a sulfur protecting group (e.g., trityl). Alternatively, R 5’ Instead of S-CH2-CH2-NH2, the SS dimer (S-CH2CH2NH2)2 can be used. The starting material (H) is optionally bonded to a protected 2-aminoethanethiol to obtain intermediate (J), which is then (optionally) deprotected and cyclized to obtain the corresponding benzothiazepine derivative of formula (A) or its salt, e.g., hydrochloride or hydrobromide. Intermediate (J) may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0205] Alternative Synthesis Examples
[0175] In some embodiments, the present disclosure provides a method for preparing the compound of formula (IV). The general route of synthesis (ROS) is described in Scheme 7:
[0206] [ka]
[0207] (In the formula, - R 1 These are halogens, haloalkyls, or haloalkyloxys. - n is 1, 2, 3, or 4. - R 2 is a halogen or PG, where PG is a nitrogen protecting group. - X is a leaving group as defined in Scheme 1.
[0176] In one embodiment of Scheme 7, (route [a]) an amine starting material (A') is reacted with an acylation reagent such as phosgene, triphosgene, carbonyldiimidazole, thionyl chloride, or 4-nitrophenyl chloroformate to obtain an acyl intermediate (B'), which is then piperazine (R 2 =H) or its protective derivative (R 2 The intermediate (C'') is obtained by reacting the amine starting material (A') with an acylated piperazine derivative, optionally in the presence of a base. In the alternative route [b], the amine starting material (A') is reacted with an acylated piperazine derivative to obtain the intermediate (C''). If a protecting group is present, it is then removed to obtain the compound of formula (IV). Preparation of starting material (A')
[0177] The amine starting material (A') can generally be prepared as described in Scheme 8 (Method 1'), Scheme 9 (Method 2'), or Scheme 10 (Method 3'), as described above for the preparation of compound (A).
[0208]
[0178] Method 1'-
[0209] [ka]
[0210]
[0179] In scheme 8, R 1 And n are as defined above, R 3’ is alkyl or aryl, R 4’ is H or PG, where PG is a nitrogen protecting group. The starting material (D') is optionally cyclized in the presence of a base to obtain the corresponding benzothiazepanone (E'), which is reduced to compound (A') or its salt, e.g., hydrochloride or hydrobromide. Any of the bases described herein can be used for this purpose. The amine group of the starting material (D') can optionally be protected, in which case the protecting group is removed before cyclization. The starting material (D') may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0211]
[0180] Method 2'-
[0212] [ka]
[0213]
[0181] In scheme 9, R 1 And n are as defined above, X' is the leaving group for X as defined above, and R 4’ is H or PG, where PG is a nitrogen protecting group. The starting alcohol (F') is reacted with an activator to introduce group X', and then the intermediate (G') is cyclized optionally in the presence of a base to obtain the corresponding benzothiazepine derivative of formula (A') or its salt, e.g., hydrochloride or hydrobromide. Any of the bases described herein can be used for this purpose. The amine group of the starting material (G') can optionally be protected, in which case the protecting group is removed before cyclization. The starting material (F') and / or intermediate (G') may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0214]
[0182] Method 3'-
[0215] [ka]
[0216]
[0183] In scheme 10, R 1 and n are as defined above, X and X' are the leaving groups defined above, and R 5 is H or PG', where PG' is a sulfur protecting group (e.g., trityl). Alternatively, R 5’Instead of S-CH2-CH2-NH2, the SS dimer (S-CH2CH2NH2)2 may be used. The starting material (H') is optionally bonded to a protected 2-aminoethanethiol to obtain intermediate (J'), which is then (optionally) deprotected and cyclized to obtain the corresponding benzothiazepine derivative of formula (A') or its salt, e.g., hydrochloride or hydrobromide. Intermediate (J') may be in the form of a free amine or an acid addition salt, e.g., hydrochloride or hydrobromide.
[0217]
[0184] In some embodiments, compounds of formula (I), (I''), (II), (III), or (IV) can be converted to pharmaceutically acceptable salts, for example, salts with pharmaceutically acceptable acids. Salts of compounds of formula (I), (I'), (II), (III), or (IV) can be prepared by reacting the parent molecule with a suitable acid (e.g., hydrobromic acid, hydrofluoric acid, trifluoroacetic acid, sulfuric acid, phosphoric acid, acetic acid, succinic acid, citric acid, lactic acid, maleic acid, fumaric acid, palmitic acid, cholic acid, pamoic acid, mucinic acid, D-glutamic acid, D-camphoric acid, glutaric acid, phthalic acid, tartaric acid, lauric acid, stearic acid, salicylic acid (salicyclic acid), methanesulfonic acid, benzenesulfonic acid, sorbic acid, picric acid, benzoic acid, cinnamic acid). In some embodiments, the salt is a hydrochloride salt. In some embodiments, the compounds can also be isolated directly as salts without proceeding via free amine bases. This result can be achieved, for example, by removing the protecting group with an acid that directly forms an acid addition salt with the compounds of formula (I), (I'), (II), (III), or (IV). Non-limiting examples of suitable acids are as described above.
[0218]
[0185] The properties of the bases used in the reactions described herein are not limiting. Non-limiting examples of bases include organic bases such as acyclic amines (e.g., trimethylamine, triethylamine, N,N-dimethylphenylamine, N,N-diisopropylethylamine (DIEA), and tributylamine), cyclic amines (e.g., N-methylmorpholine), and tertiary amines including aromatic amines (dimethylaniline, dimethylaminopyridine, and pyridine).
[0219]
[0186] Protecting groups can mask functional groups during method steps in which the functional groups would otherwise react in an undesirable manner. The protecting groups are then removed to expose the original functional groups. Removal or deprotection is performed after the completion of the reaction or after the reaction in which the functional groups interfere.
[0220]
[0187] In some embodiments, the functional group to be protected is an amine group. Suitable protecting groups include, for example, a group of the formula -C(=O)-R, where R is (C1-C4) alkoxy, allyloxy, benzyloxy, substituted benzyloxy, fluorenyl methoxy, or adamantyloxy. Non-limiting examples of nitrogen protecting groups include t-butoxycarbonyl (BOC), benzyloxycarbonyl, substituted benzyloxycarbonyl, or fluorenyl methoxycarbonyl (FMOC). Further nitrogen protecting groups include trityl, acyl (e.g., trifluoroacetyl), alkylaryl (e.g., benzyl), OSO2R' where R' is alkyl or aryl (e.g., OMs (mesylates) and OTs (tosylates)).
[0221]
[0188] Other suitable protecting groups are discussed in standard textbooks in the field of chemistry, for example, Protective Groups in Organic Synthesis by T.W. Greene and P.G.W. Mutts [John Wiley & Sons, New York, 1999], which is incorporated herein by reference as if it were fully described herein. Of particular note is the chapter titled “Protection for the Amino Group” (pp. 494–614).
[0222]
[0189] The reaction can be carried out in or without a solvent. If a solvent is used, its properties are not limited, and examples include esters (e.g., ethyl acetate), ethers (e.g., THF), chlorinated solvents (e.g., dichloromethane or chloroform), dimethylformamide (DMF), and other solvents such as acetonitrile or toluene, or mixtures of these solvents with each other or with water. [Examples]
[0223] Example 1 General synthesis method
[0190] Equipment - NMR: Bruker AVANCE III 400 or Varian Mercury 300 - LC / MS: Waters Delta 600 with Autosampler 717Plus, Photo Diode-Array Detector 2996, and Mass Detector 3100, or Shimadzu 210.
[0224] Example 1A.
[0191] General procedure for the preparation of substituted 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine ("amine", compound A) (Method 1, Scheme 4).
[0225] [ka]
[0226]
[0192] To a stirred solution of Boc-protected ester (D) (100 mmol) in an organic solvent, TFA or HCl (excess) was added. The solution was stirred at room temperature to remove the TFA and organic solvent. The residue was dissolved in an organic solvent and sodium methoxide (200 mmol) was added. The reaction mixture was stirred overnight in RT, and the solvent was removed under reduced pressure. The residue was washed with water / acid, and the precipitate was collected and dried to obtain pure lactam (E).
[0227]
[0193] A stirring solution of lactam(E) in an anhydrous organic solvent was prepared by adding a reducing agent such as boranetetrahydrofuran (BH3:THF) or lithium aluminum hydride (2 equivalents) at 0°C. The reaction mixture was heated under reflux and stirred overnight, then quenched with methanol. The mixture was refluxed for 1 hour, and the solvent was removed by evaporation. The residue was suspended in ethanol, treated with concentrated HCl, and then the solvent was removed. Unreacted starting materials were removed by precipitation from an acidic aqueous solution and filtration, and the product was isolated by further organic extraction. The aqueous solution was made basic, and the product was obtained by organic extraction.
[0228] Example 1B.
[0194] General procedure for the preparation of substituted 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine ("amine", compound A) (Method 2, Scheme 5)
[0195] Thionyl chloride was added dropwise in an organic solvent to the stirred solution of (F) protected with Boc. The reaction mixture was stirred at 0°C and then heated to RT. The reaction was quenched with alcohol. After removal of the solvent, the desired crude product (G) was obtained.
[0229]
[0196] A base such as DIEA or i-Pr2Et was added to the stirred solution of compound (G) obtained above in an organic solvent, and the reaction was stirred overnight at RT. After removing the solvent, the residue was purified by silica gel column chromatography to obtain the product as a white solid.
[0230] Example 1C.
[0197] General procedure for the preparation of substituted 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine ("amine", compound A) (Method 3, Scheme 6)
[0198] Trityl-protected cystamine was added to a stirred solution of the benzyl derivative (H) in an organic solvent in the presence of a base, and the reaction was stirred by RT. The solvent was removed, and the residue was purified by column chromatography to obtain intermediate (J).
[0231]
[0199] Intermediate (J) was dissolved in an organic solvent, the trityl group was removed with TFA / Et3SiH, and then the solvent and TFA were removed. The residue was mixed with CuI in alcohol and a base, the reaction mixture was refluxed overnight, cooled to RT, and then the product was isolated by filtration.
[0232] Example 1D.
[0200] General procedure for amidation of substituted 2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (amine A) (Scheme 3, 3a)
[0233] [ka]
[0234]
[0201] Route [a]: Amine (A) (1 mmol) was dissolved in an organic solvent. An acylation reagent (1 mmol), followed by a base (2 mmol), was added to the solution. The mixture was stirred at room temperature for 0.5 to 1 hour. The reaction was then quenched in aqueous solution at 0°C. The organic phase was separated and dried over anhydrous sodium sulfate. After evaporation of the solvent and optional purification, the intermediate was reacted with Boc-piperazine (2 mmol) and a base (2.5 mmol) in an organic solvent. The reaction mixture was stirred at 0°C for 0.5 to 1 hour and overnight at room temperature. The mixture was washed with aqueous solution and dried over anhydrous sodium sulfate. The solution was then filtered and concentrated. The residue was purified by silica gel column chromatography.
[0235]
[0202] Route [b]: Alternatively, amine (A) was dissolved in an organic solvent and mixed with Boc-protected chlorocarbonylpiperazine. The solution was stirred at room temperature for 24 hours and the reaction solution was evaporated to dryness. The Boc protecting group was removed with TFA. The residue was purified by silica gel column chromatography.
[0236] Example 2 Preparation of 1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 1·1HCl)
[0203] Compound (1) was prepared according to route [a] of scheme (3) or (3a) and method 1 (scheme 4):
[0237] [ka]
[0238]
[0204] i) Methyl 2-fluoro-4-(trifluoromethyl)benzoate
[0239] [ka]
[0240]
[0205] To a stirred solution of 2-fluoro-4-(trifluoromethyl)benzoic acid (24.0 g, 115.3 mmol) in anhydrous toluene (100 ml), thionyl chloride (20 ml, 32.7 g, 275 mmol, 2.4 equivalents) and anhydrous DMF (5 drops) were added. The reaction mixture was refluxed for 3 hours. After removing the solvent under reduced pressure, the residue was evaporated once with toluene (30 ml). The residue was then dissolved in anhydrous CH2Cl2 (100 ml). This solution was then slowly added to anhydrous methanol (100 ml) at 0°C with stirring. The resulting mixture was stirred at room temperature over the weekend. After removal of the solvent, a colorless crude oil product was obtained. The crude product was essentially pure. No further purification was attempted.
[0241]
[0206] 1 H-NMR (300 MHz, CDCl3): 8.07 (t,1H), 7.45 (m, 2H), 3.97 (s, 3H).
[0242]
[0207] ii) Methyl 2-(2-(tert-butoxycarbonylamino)ethylthio)-4-(trifluoromethyl)benzoate
[0243] [ka]
[0244]
[0208] To a stirred solution of methyl 2-fluoro-4-(trifluoromethyl)benzoate (1.00 g, 4.50 mmol) in anhydrous MeCN (10 ml), 2-(Boc-amino)ethanethiol (0.80 ml, 839.2 mg, 4.73 mmol, 1.05 equivalents) and K2CO3 (1.86 g, 13.47 mmol, 3 equivalents) were added. The mixture was degassed, replenished three times with Ar, and refluxed overnight. The solvent was then removed under reduced pressure. The residue was dissolved in CH2Cl2 (100 ml) and H2O (100 ml). The organic phase was separated. The aqueous phase was extracted with CH2Cl2 (100 ml). The combined CH2Cl2 phase was dried over anhydrous sodium sulfate and filtered. A colorless oil was obtained by removing the solvent, which turned into a white solid after drying under high vacuum. The product was used in the next step without further purification.
[0245]
[0209] 1 H-NMR (300 MHz, CDCl3): 8.05 (d, 1H), 7.61 (s, 1H), 7.42 (d, 1H), 4.98 (br. S, 1H), 3.95 (s, 3H), 3.46 (q, 2H, q), 3.15 (t, 2H), 1.44 (s, 9H).
[0246]
[0210] iii) 8-(trifluoromethyl)-3,4-dihydrobenzo[f][1,4]thiazepine-5(2H)-one
[0247] [ka]
[0248]
[0211] Trifluoroacetic acid (5 ml) was added to a stirred solution of methyl 2-(2-(tert-butoxycarbonylamino)ethylthio)-4-(trifluoromethyl)benzoate (1.60 g, 4.22 mmol) in CH2Cl2 (5 ml). The mixture was stirred at room temperature for 2 hours. An oil product was obtained by removing the solvent under reduced pressure, which became a white solid after drying under high vacuum for 2 hours.
[0249]
[0212] The above white solid crude product was dissolved in anhydrous MeOH (20 ml) and treated overnight at room temperature with a solution of NaOMe in MeOH (4.375 M, 1.93 ml, 8.44 mmol). After removing the solvent, the residue was treated with 1 M citric acid / H2O at room temperature for 0.5 hours. The mixture was filtered, the white solid was washed with H2O (10 ml x 3) and dried under high vacuum. 0.85 g of pure white solid product was obtained.
[0250]
[0213] 1 H-NMR (300 MHz, CDCl3): 7.82-7.80 (m, 2H), 7.70-7.67 (m, 1H), 7.09 (br. S, 1H), 3.41 (q, 2H, q), 3.22 (t, 2H).
[0251]
[0214] iv. 8-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine
[0252] [ka]
[0253]
[0215] To a stirred solution of 8-(trifluoromethyl)-3,4-dihydrobenzo[f][1,4]thiazepine-5(2H)-one (18.69 g, 75.67 mmol) in anhydrous THF (200 ml) at 0°C, boranetetrahydrofuran complex solution (1 M in THF, 151.3 ml, 151.3 mmol, 2 equivalents) was added dropwise. The reaction mixture was heated under reflux overnight. Then, MeOH (100 ml) was slowly added to the mixture at 0°C, and the mixture was heated under reflux for 1 hour. After removing the solvent, the oil residue was suspended in MeOH (200 ml) and treated with concentrated HCl (40 ml). After 2 days under reflux, the mixture was still a cloudy solution. Then, the solvent was removed under reduced pressure. The residue was suspended in EtOH (150 ml) and treated with concentrated HCl (30 ml) for 24 hours until the solution became clear. After removing the solvent, the residue was treated with H2O (250 ml). By filtering the turbid mixture, a white solid, representing the unreacted starting material, was obtained. The filtrate was washed with siRNA (50 ml, 80 ml, and 100 ml). The combined siRNA phase was dried over anhydrous sodium sulfate and filtered. By removing the solvent, a white solid compound, representing the unreacted starting material, was obtained (total recovered starting material, 5.50 g, 29%). The aqueous phase was treated with NaOH / H2O to pH=14. The product was extracted with CH2Cl2 (100 ml x 3). The combined CH2Cl2 phase was dried over anhydrous sodium sulfate and filtered. By removing the solvent, the desired product was obtained as a colorless oil.
[0254]
[0216] 1 H-NMR (300 MHz, CDCl3): 7.82 (s, 1H), 7.46-7.42 (m, 1H), 7.34-7.31 (m,1H), 4.17 (s, 2H), 3.42-3.38 (m, 2H), 2.81-2.78 (m, 2H).
[0255]
[0217] v.8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carbonyl chloride
[0256] [ka]
[0257]
[0218] To a stirred solution of triphosgene (300 mg, 1.01 mmol) in CH2Cl2 at 0°C, a solution of 8-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (300 mg, 1.29 mmol) and pyridine (0.83 ml, 808 mg, 101.1 mmol) in CH2Cl2 (5 ml) was slowly added over 10 minutes. The reaction mixture was stirred at 0°C for 30 minutes. The reaction was then quenched by adding 0.5 N HCl / H2O solution (20 ml) at 0°C. The CH2Cl2 phase was separated and dried over anhydrous sodium sulfate. After filtration and solvent removal, the residue was purified by silica gel column chromatography. 0.32 g of the product 8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carbonyl chloride was obtained as a colorless oil.
[0258]
[0219] vi.tert-butyl4-(8-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-4-carbonyl)piperazine-1-carboxylate
[0259] [ka]
[0260]
[0220] A solution of Boc-piperazine (360 mg, 1.93 mmol) and pyridine (0.21 ml, 199 mg, 2.49 mmol) in CH2Cl2 (10 ml), stirred at 0°C, was combined with a solution of 8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carbonyl chloride (product from the above step, 0.32 g, 1.08 mmol) in CH2Cl2 (10 ml). The reaction mixture was stirred at 0°C for 0.5 hours and overnight at room temperature. After dilution with CH2Cl2 (50 ml), the mixture was washed with saturated NaHCO3 / H2O (20 ml), 1 M citrate / H2O (20 ml x 2), and H2O (20 ml). After drying over anhydrous sodium sulfate, the solution was filtered and concentrated. The residue was purified by silica gel column chromatography. The product tert-butyl 4-(8-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-4-carbonyl)piperazine-1-carboxylate was obtained as a colorless oil.
[0261]
[0221] 1 H-NMR (300 MHz, CDCl3): 7.79 (s, 1H), 7.50-7.40 (m, 2H), 4.97 (s, 2H), 3.99 (m, 2H), 3.42 (m, 4H), 3.18 (m, 4H), 2.95 (m, 2H), 1.46 (s, 9H).
[0262]
[0222] vii. Piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone(1)
[0263] [ka]
[0264]
[0223] Trifluoroacetic acid (5 ml) was added to a stirred solution of tert-butyl 4-(8-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-4-carbonyl)piperazine-1-carboxylate (product obtained from the above step, 0.46 g, 1.03 mmol) in CH2Cl2 (5 ml). The mixture was stirred at room temperature for 5 hours. After removing the solvent under reduced pressure, the residue was dissolved in H2O (50 ml) and washed with ether (25 ml x 2). The aqueous phase was treated with NaOH / H2O to pH=12. The product was extracted with CH2Cl2 (30 ml x 3). The combined organic phase was dried over anhydrous sodium sulfate and filtered. By removing the solvent, the desired product, piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (1), was obtained as a white solid.
[0265]
[0224] viii. Piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone(1·HCl)
[0266] [ka]
[0267]
[0225] To a stirred solution of piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone (1) (0.36 g, 1.04 mmol) in ether (20 ml), 1 M HCl / ether solution (2 ml, 2 mmol) was added. The mixture was stirred at room temperature for 0.5 hours. The solvent was removed. The residue was washed once with ether (1 ml) and dried under high vacuum. The desired product, piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (1·HCl), was obtained as a yellow solid.
[0268]
[0226] 1H-NMR (300 MHz, DMSO-d6): 8.86 (br. S, 2H), 7.69 (1H, s), 7.57 (s, 2H), 4.56 (s, 2H), 3.71 (m, 2H), 3.24 (m, 4H), 3.09 (m, 6H).
[0269] Example 3 Preparation of piperazine-1-yl (7-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 2·HCl)
[0227] Compound (2) was prepared using the general synthesis method described in Example 1, following the scheme (3) or (3a) route [b] and method 1 (scheme 4).
[0270] [ka]
[0271] i) Methyl 5-trifluoro-2-chlorobenzoic acid
[0272] [ka]
[0273]
[0228] 1 HNMR (300 MHz, CDCl3): 8.05 (d, 1H), 7.63 (dd, 1H), 7.56 (d, 1H), 3.97 (s, 3H).
[0274]
[0229] iii) Methyl 2-((2-((tert-butoxycarbonyl)amino)ethyl)thio)-5-(trifluoromethyl)benzoate
[0275] [ka]
[0276]
[0230] 1HNMR (300 MHz, CDCl3): 8.21 (d, 1H), 7.63 (d, 1H), 7.56 (d, 1H), 4.98 (br s, 1H), 3.97 (s, 3H), 3.44 (q, 2H), 3.10 (t, 2H), 1.45 (s, 9H). iii) 7-(trifluoromethyl)-3,4-dihydrobenzo[f][1,4]thiazepine-5(2H)-one
[0277] [ka]
[0278]
[0231] 1 HNMR (300 MHz, DMSO-d6): 8.62 (t, br, 1H), 7.70-7.60 (m, 3H), 3.22 (m, 4H).
[0279]
[0232] iv. 7-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine HCl
[0280] [ka]
[0281]
[0233] 1 HNMR (300 MHz, DMSO-d6): 9.60 (brs, 1H), 8.03 (s, 1H), 7.80 (d, 1H), 7.70 (d, 1H), 4.50 (s, 2H), 3.50 (m, 2H), 3.12 (m, 2H).
[0282]
[0234] v.tert-butyl4-(7-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-4-carbonyl)piperazine-1-carboxylate
[0235] The amine hydrochloride (1.1 mmol), DIEA (0.7 ml, 3.7 mmol), and 4-chlorocarbonyl-piperazine-1-carboxylic acid tert-butyl ester (300 mg, 1.2 mmol) obtained above were mixed in 5 ml of dichloromethane. The solution was stirred at room temperature (RT) for 24 hours. The reaction solution was evaporated to dryness. The residue was dissolved in 2 ml of dichloromethane and loaded onto a column. The column was washed with ethyl acetate / hexane.
[0283] [ka]
[0284]
[0236] 1 HNMR (300 MHz, CDCl3): 7.59 (m, 2H), 7.41 (d, 1H), 4.54 (s, 2H), 3.77 (m, 2H), 3.42 (m, 4H), 3.13 (m, 4H), 2.95 (m, 2H), 1.44 (s, 9H).
[0285]
[0237] vi. Piperazine-1-yl(7-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)yl)methanone hydrochloride (2·HCl)
[0238] To a stirred solution of tert-butyl 4-(7-(trifluoromethyl)-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-4-carbonyl)piperazine-1-carboxylate (0.47 g, 1.05 mmol) in ether (3 ml), 4 M HCl / dioxane solution (5 ml, 20 mmol) was added. The solution was stirred at RT for 3 hours. The solvent and excess HCl were removed, the residue was washed with ether (10 ml), and dried under high vacuum to retain the target product.
[0286]
[0239] 1HNMR (300 MHz, DMSO-d6): 9.20 (br, 2H), 7.55 (m, 3H), 4.55 (s, 2H), 3.69 (m, 2H), 3.24 (m, 4H), 3.14 (m, 6H).
[0287] Example 4 Compounds 3-10 were prepared by amidation according to the general methods 1-3 for preparing amine (A), followed by the steps in scheme (3) or (3a).
[0288] Example 4A.
[0240] Piperazine-1-yl (9-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 3·HCl)
[0289] [ka]
[0290]
[0241] Compound 3 was prepared according to the scheme (3) or (3a) route [b] and method 1 (scheme 4).
[0291]
[0242] 1 HNMR (300 MHz, DMSO-d6): 9.20 (br, 2H), 7.67 (m, 2H), 7.46 (t, 1H), 4.58 (s, 2H), 3.69 (m, 2H), 3.24 (m, 4H), 3.14 (m, 6H).
[0292] Example 4B.
[0243] Piperazine-1-yl (7-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 4·HCl)
[0293] [ka]
[0294]
[0244] Compound (4) was prepared according to the scheme (3) or (3a) route [b] and method 3 (scheme 6).
[0295]
[0245] 1-Bromo-2-(bromomethyl)-4-(trifluoromethoxy)benzene (54 mmol), trityl-protected cysteamine (54 mmol), and DIEA (112 mmol) were stirred in 200 ml of acetonitrile at RT for 3 hours. The solvent was removed and the residue was loaded directly onto the column. The column was washed with chloroform and then ethyl acetate to obtain the following intermediate:
[0296] [ka]
[0297]
[0246] The above compound (21 g, 36.7 mmol) was dissolved in 20 ml of dichloromethane and 60 ml of TFA. Triethylsilane (14 ml, 88 mmol) was slowly added to the solution over 30 minutes. The solution was stirred for a further 2 hours under RT. The solvent and TFA were removed under reduced pressure. The residue was subjected to a high vacuum pump for a further 2 hours.
[0298]
[0247] The above residue was mixed with CuI (700 mg, 3.7 mmol) and potassium carbonate (20 g, 145 mmol) in 150 ml of isopropanol. The mixture was stirred overnight under reflux. After cooling to RT, 300 ml of dichloromethane was added, and the solid was removed by filtration. The intermediate was analyzed using a column with chloroform and methanol as eluents:
[0299] [ka]
[0300] By forming [the desired compound], the desired thiazepine was obtained.
[0301]
[0248] 1HNMR (300 MHz, CDCl3): 7.65 (d, 1H), 7.24-7.14 (m, 2H), 4.23 (s, 2H), 3.60 (m, br, 2H), 3.05 (m, 2H).
[0302]
[0249] The amine intermediate was converted to compound (4) using the general method of scheme (3) or (3a) or route [b] described in Example 2.
[0303]
[0250] 1 HNMR (300 MHz, DMSO-d6): 9.20 (br, 2H), 7.53 (d, 1H), 7.38 (d, 1H), 7.20 (dd, 1H), 4.49 (s, 2H), 3.69 (m, 2H), 3.24 (m, 4H), 3.04 (m, 6H).
[0304] Example 4C.
[0251] Piperazine-1-yl (6-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 5·HCl)
[0305] [ka]
[0306]
[0252] Compound (5) was prepared according to the scheme (3) or (3a) route [b] and method 2 (scheme 5).
[0307]
[0253] 1 H-NMR (300 MHz, DMSO-d6): 9.18 (br. s, 2H), 7.60 (t, 2H ), 7.35 (t, 1H), 4.72 (s, 2H), 3.62 (m, 2H), 3.26 (m, 6H), 3.03 (m, 2H).
[0308] Example 4D.
[0254] (7,8-difluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone hydrochloride (compound 6·HCl)
[0309] [ka]
[0310]
[0255] Compound (6) was prepared according to scheme (3) or route (3a) [b] and method 3.
[0311]
[0256] 1 H-NMR (300 MHz, DMSO-d6): 9.01 (br. S, 2H), 7.56-7.42 + 7.27-7.19 (m, 2H), 4.45 (s, 2H), 3.70-3.66 (m, 2H), 3.26-3.23 (m, 4H), 3.09 (br. S, 4H), 3.01-2.98 (m, 2H).
[0312] Example 4E.
[0257] (6-chloro-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone hydrochloride (compound 7·HCl)
[0258] Compound (7) was prepared according to the scheme (3) or (3a) route [b] and method 2.
[0313] [ka]
[0314]
[0259] 1 HNMR (300 MHz, DMSO-d6): 9.17 (br, 2H), 7.32 (m, 2H), 7.10 (t, 1H), 4.69 (s, 2H), 3.64 (m, 2H), 3.28 (m, 4H), 3.17 (m, 2H), 3.04 (m, 4H).
[0315] Example 4F.
[0260] Piperazine-1-yl (6-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone hydrochloride (compound 8·HCl)
[0316] [ka]
[0317]
[0261] Compound (5) was prepared according to scheme (3) or route (3a) [b] and method 3.
[0318]
[0262] 1 H-NMR (300 MHz, DMSO-d6): 8.50 (br. s, 2H), 7.38 (m, 1H), 7.25 (m, 2H), 4.62 (s, 2H), 3.68 (m, 2H), 3.26 (m, 4H), 3.18(m, 2H), 3.05 (m, 4H).
[0319] Example 4G
[0263] (6-bromo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone hydrochloride (compound 9·HCl)
[0320] [ka]
[0321]
[0264] Compound (9) was prepared according to the scheme (3) or (3a) route [b] and method 2.
[0322] [ka]
[0323]
[0265] (i)tert-butyl 2-(3-bromo-2-formylphenylthio)ethylcarbamate
[0324] [ka]
[0325]
[0266] A solution of 2-(Boc-amino)ethanethiol (4.09 g, 23.06 mmol) in THF (10 ml) was added dropwise to a stirred solution of NaH (60% of the oil, 0.97 g, 24.14 mmol) in anhydrous THF (10 ml) at 0°C. The reaction mixture was stirred at 0°C for 3 hours. Then, a solution of 2-bromo-6-fluorobenzaldehyde (3.9 g, 19.21 mmol) in THF (10 ml) was added. The resulting mixture was stirred overnight at RT. After removing the solvent under reduced pressure at RT, the residue was treated with ice / water (50 ml). The product was extracted with CH2Cl2 (200 ml x 3). The combined organic phase was dried over anhydrous sodium sulfate and filtered. By removing the solvent, the crude product was obtained as a brown oil.
[0326]
[0267] (ii) tert-butyl 2-(3-bromo-2-(hydroxymethyl)phenylthio)ethylcarbamate
[0327] [ka]
[0328]
[0268] To a stirred solution of the crude mixture from step (i) in anhydrous ethanol (100 ml), NaBH4 (778 mg, 20.57 mmol) was added. The reaction mixture was stirred at RT for 1 hour. Then, an additional NaBH4 (2.2 g) was added, and the reaction mixture was stirred at RT for a further 2 hours. After quenching the reaction with ice / water (100 ml), the solvent ethanol was removed. The product was extracted with CH2Cl2 (200 ml × 4). The combined organic phases were dried over anhydrous sodium sulfate and filtered. After removal of the solvent, the residue was purified by silica gel column. The desired product [tert-butyl 2-(3-bromo-2-(hydroxymethyl)phenylthio)ethyl carbamate] was obtained as a white solid.
[0329]
[0269] 1 H-NMR (300 MHz, CDCl3): 7.49-7.42 (m, 2H), 7.12 (t, 1H), 5.20 (br. s, 1H,), 5.04 (d, 2H), 3.29 (q, 2H), 3.06 (t, 2H), 2.57 (t, 1H), 1.41 (s, 9H).
[0330]
[0270] (iii) 2-(3-bromo-2-(chloromethyl)phenylthio)ethanamine hydrochloride
[0331] [ka]
[0332]
[0271] To a stirred solution of tert-butyl 2-(3-bromo-2-(hydroxymethyl)phenylthio)ethyl carbamate (3.91 g, 10.79 mmol) in CHCl3 (30 ml) at 0°C, thionyl chloride (2.83 ml, 4.62 g, 38.84 mmol) was added dropwise. The reaction mixture was stirred at 0°C for 1 hour and at 50°C for 5 hours. Then, 50 ml of MeOH was added at 0°C, and the mixture was stirred at RT for 1 hour. After removal of the solvent, the desired crude product was obtained.
[0333]
[0272] 1 H-NMR (300 MHz, DMSO-d6): 8.20 (br. s, 3H), 7.61-7.55 (m, 2H), 7.31 (m, 1H), 4.97 (s, 2H), 3.30 (m, 2H), 2.95 (m, 2H).
[0334]
[0273] (iv) 6-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine
[0335] [ka]
[0336]
[0274] To a stirred solution of 2-(3-bromo-2-(chloromethyl)phenylthio)ethanamine hydrochloride (crude product obtained from the final step reaction, 10.79 mmol) in MeCN (300 ml), i-Pr2NEt (10 ml, excess) was added. The reaction mixture was stirred overnight in RT. After removing the solvent, the residue was purified by silica gel column. The desired product was obtained as a white solid.
[0337]
[0275] 1 H-NMR (300 MHz, CDCl3): 7.50 (dd, 1H), 7.46 (dd, 1H), 6.96 (t, 1H), 4.43 (s, 2H), 3.38-3.34 (m, 2H), 2.85-2.81 (m, 2H).
[0338]
[0276] The above product was converted to compound (9)HCl salt using the general method described in Examples 1 and 2.
[0339]
[0277] 1 H-NMR (300 MHz, DMSO-d6): 8.91 (br. s, 2H), 7.49 (dd, 1H), 7.33 (dd, 1H), 7.06 (t, 1H), 4.70 (s, 2H), 3.65-3.61 (m, 2H), 3.27-3.25 (m, 4H), 3.21-3.17 (m, 2H), 3.07 (m, 4H).
[0340] Example 4H
[0278] (6-iodo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone hydrochloride (compound 10·HCl)
[0279] Compound (10) was prepared according to the scheme (3) or (3a) route [b] and method 2.
[0341] [ka]
[0342]
[0280] 1 HNMR (300 MHz, DMSO-d6): 9.17 (br s, 2H), 7.53 (d, 1H), 7.33 (d, 1H), 6.87 (t, 1H), 4.64 (s, 2H), 3.61 (m, 2H), 3.28 (m, 4H), 3.17 (m, 2H), 3.15 (m, 4H).
[0343] Example 5 Inhibition of unstimulated calcium release events in cardiomyocytes.
[0281] The compounds of this disclosure were evaluated for their effect on inhibiting isoproterenol-induced unstimulated calcium release events in cardiomyocytes isolated from mouse hearts. Experimental protocol
[0282] Adult cardiomyocytes are isolated from 28-32 gram female C57BL / 6 mice using a perfusion solution containing Liberase TH (Sigma Aldrich, #05-401-151001). After isolation, Ca is extracted at 4-minute intervals in 5 steps. 2+ Reintroduce the compound. Then plate the cells in 100 μl of cardiomyocyte culture medium (MEM, Invitrogen, #11575-032) containing brevistatin and compound treatments at various concentrations (0.01-10 μM) at a density of 5000-7000 rod-shaped cells (time zero). One hour after compound treatment, treat the cells with isoproterenol (1 μM). Two hours after compound treatment, add Ca to the cells. 2+ Load the indicator (Fluo-4-AM, Invitrogen #F14202). Three hours after compound treatment, quickly but gently remove the MEM and record the cells for field stimulation using a custom-designed electrode in a recording solution (Ca 2+ Resuspend the cells in 2 mM (1 μM) isoproterenol. Stimulate the cells at 0.5 Hz for 20 seconds, then at 5 Hz for 5 seconds. Data Analysis
[0283] 1 study = 3 experiments. 1 experiment = 1 mouse. Each experiment consists of 3 sets of 3 controls. A) Ca 2+ B) Ca 2+ + Isoproterenol C)Ca 2+ +Isoproterenol+Control compound
[0284] The first step of the analysis is to determine the number of responders based on four conditions. The responders are then analyzed to determine the number of unstimulated calcium release events, which are peaks of sufficient intensity measured during the period after a 5 Hz stimulus. Effect of the test compound (triple Ca 2+ The inhibition rate (+isoproterenol + test compound) is expressed as the inhibition rate of control B versus A. result
[0285] The inhibition of non-stimulated calcium release events is summarized in Table 1. All compounds were tested at 10 μM.
[0344] [Table 1]
[0345] Example 6 Bioavailability, pharmacokinetics, and brain exposure
[0286] The compounds of this disclosure were evaluated for oral bioavailability, pharmacokinetics, and brain exposure. method
[0287] Analytical instrument: Waters Acquity Class H UPLC with Waters SQ3100 mass detector.
[0346]
[0288] 1) Initial non-terminal assessment of the oral bioavailability and plasma pharmacokinetics of a compound.
[0347]
[0289] Sprague-Dawley rats were administered 20 mg / kg via oral enteral nutrition, and blood samples were collected at 30 minutes, 1 hour, 4 hours, and 12 hours. Plasma concentrations were determined by UPLC / MS. The 12-hour exposure (AUC12, Table 2) was determined by trapezoidal integral of the observed concentrations.
[0348]
[0290]
[0349] [Table 2]
[0350] 2) Assessment of brain exposure.
[0351]
[0291] Brain and plasma concentrations 4 hours after oral administration (corresponding to Tmax in the first experiment) were determined by UPLC / MS, and the corresponding brain-to-plasma ratio was calculated. The results are reported in Table 3.
[0352]
[0292]
[0353] [Table 3]
[0354]
[0293] 3) Evaluation of the pharmacokinetics of compound 2 by intravenous (IV) administration
[0294] To complement the oral PK data and determine the absolute oral bioavailability, additional PK parameters were obtained using intravenous administration. The compound was administered by tail vein injection, and blood samples were taken at 30 minutes, 1 hour, 4 hours, and 12 hours. Plasma drug concentrations were determined by UPLC / MS.
[0355]
[0295] The concentration results were used to estimate PK parameters (i.e., C0, T1 / 2, Vd, AUCinf) based on noncompartmental distribution and mono-exponential concentration decay. The half-life values thus obtained were also used to estimate AUCinf in the case of PO administration.
[0356]
[0296] A comprehensive overview of PK results after IV and PO administration, including the brain-to-plasma ratio, is shown in Table 4.
[0357]
[0297]
[0358] [Table 4]
[0359] 4. Plasma and brain exposure
[0298] The morning and evening plasma and tissue (brain) exposure levels measured after one week of administration are reported in Table 5. The exposure results after one week of administration confirmed that compound 2 has brain exposure. Plasma and tissue exposure levels were higher in the morning than in the evening.
[0360]
[0299]
[0361] [Table 5]
[0362] Example 7 Binding of Calstabine 2 to PKA-phosphorylated RyR2
[0300] Calstabin 2 was bound to PKA-phosphorylated RyR2. Cardiac sarcoplasmic reticulum (CSR) was PKA-phosphorylated and incubated with calstabin 2 at room temperature for 30 minutes. The reaction mixture was rotated by centrifugation, the resulting pellet was washed, and the supernatant was discarded. Proteins were separated using SDS / PAGE. Calstabin 2 binding was detected using anti-calstabin 2 (primary antibody) and a suitable secondary antibody.
[0363]
[0301] The compounds of this disclosure prevented dissociation and promoted the recombination of calstabine 2 to PKA-phosphorylated RyR2 at a concentration of 100 nm.
[0364] Example 8 Binding of Calstabine 1 to PKA-phosphorylated RyR1
[0302] The same method as in Example 1 was used to bind Calstabine 1 to PKA-phosphorylated RyR1.
[0365]
[0303] The compounds of this disclosure prevented dissociation and promoted the recombination of calstabine 1 to PKA-phosphorylated RyR1 at a concentration of 100 nm.
[0366] Example 9 Binding of calstabin 2 to RyR2 in human Huntington's disease (HD) cortical microsomes
[0304] Brain microsomes were prepared from the human hippocampus, and cortical samples were collected from HD patients. Control samples were from patients with negative neuropathological diagnoses.
[0367]
[0305] RyR2 was immunoprecipitated from cortical lysate (+ / - various concentrations of compound 2) using RyR2-specific antibody (2 μg) in 0.5 ml of modified RIPA buffer (50 mM Tris-HCl pH 7.2, 0.9% NaCl, 5.0 mM NaF, 1.0 mM Na3VO4, 1% Triton-X100, and protease inhibitor), and left overnight at 4°C. The immunocomplexes were incubated with protein A Sepharose beads at 4°C for 1 hour, and the beads were washed three times with RIPA buffer. The immunoprecipitates were separated on SDS-PAGE gel (6% gel for RyR2, 15% gel for Calstabine 2) and transferred onto a nitrocellulose membrane at 200 mA for 2 hours. Immunoblots were developed using antibodies against RyR and Calstabine. The experiment was conducted using cortical lysate from a 64-year-old woman with stage 4 HD (36 CAG repeats). As seen in Figure 1, compound 2 improves calstabine rebinding to RyR2 (repairing channel leakage) in human HD cortical microsomes.
[0368] Example 10 Compound 2 increases calstabin 2 against RyR2 in human Huntington's disease (HD) cortical microsomes - dose curve
[0306] Compound 2 or reference Rycal S107 (0-10,000 nM) was added to a double reaction containing 150 μg of human HD cortical microsomes. The binding reaction was performed at 10 nM. 35The reaction was initiated by adding S-labeled calstabine 2. The sample was incubated at RT for 1 hour. The reaction was stopped by adding ice-cold binding buffer, and then filtered through a GF / B Whatman filter pre-equilibrated with 0.015% PE. The filter was washed three times with 5 ml of washing buffer (10 mM MOPS, 200 mM NaCl, pH 7.4), dried, and counted. Nonspecific binding was determined using 10 μM rapamycin. As shown in Figure 2, compounds 2 and S107 increased calstabine 2 binding to HD microsomes, with EC50 values of 100 ± 4.8 and 155 ± 6.2 nM, respectively. The experiment was performed using cortical microsomes from two patients: a 64-year-old woman with stage 4 HD (36 CAG repeats) and a 63-year-old man with stage 4 HD (42 CAG repeats).
[0369]
[0307] The structure of S107 is shown below.
[0370] [ka]
[0371] Example 11 Compound 2 repairs RyR-mediated calcium leakage in human HD cortical microsomes.
[0372]
[0308] Human cortical microsomes (5 μg / ml) were diluted in 20 mM HEPES buffer (pH 7.2) containing 2 μM CaCl2 mixed with 7 mM NaCl, 1.5 mM MgCl2, 120 mM K-gluconate, 5 mM K-phosphate, 8 mM K-phosphocreatine, 1 μM EGTA, and 3 μM Fluo-4, and added to multiple wells of a 96-well plate. The calcium (Ca) content of the microsomes was measured. 2+ Loading was initiated by adding 1 mM ATP. Ca 2+ After ingestion, 3 μM thapsigargine was added. (A) Ca from human cortical microsomes induced by the addition of 3 μM thapsigargine. 2+Typical trace of leakage. (B)-Ca 2+ Leakage was calculated as the percentage increase in signal after the addition of thapsigargin. Data (mean ± SEM) analysis was performed by Student's t-test (n=2 for each group)**P<0.01. The experiment was conducted using cortical microsomes from two patients: a 58-year-old woman with stage 4 HD (50 CAG repeats) and a 58-year-old man with stage 4 HD (51 CAG repeats). As shown in Figure 3, compound 2 reduced calcium leakage from HD microsomes. Embodiment
[0309] Embodiment 1. Formula (I):
[0373] [ka]
[0374] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - R 2 These are, respectively, independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, and -C(O)NR 3 R 4 -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8, or -C(O)C(O)OR 8 And, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 , R 7 , and R 8 These are compounds that are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, respectively. or a pharmaceutically acceptable salt thereof however, (a)(i)R 1a , R 1b , R 1c , and R 1d (ii)R 1b (iii)R 2 Compounds in which -C(O)OtBu or -C(O)OCH2Ph are excluded. (b)R 1d When R is methyl, 2 It is not 4-methoxybenzyl, (c)R 1a When is methyl, Cl, CN, or F, or R 1b When R is Br, 2 It is not methyl, -C(=O)H, -C(=O)Me, -C(=O)Et, or -C(=O)Ph. A compound that meets the following conditions, or a pharmaceutically acceptable salt thereof.
[0375]
[0310] Embodiment 2.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the members is a haloalkyl group.
[0376]
[0311] Embodiment 3.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the compounds is trifluoromethyl.
[0377]
[0312] Embodiment 4.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of them is a halogen.
[0378]
[0313] Embodiment 5.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the elements is fluoro.
[0379]
[0314] Embodiment 6.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the elements is chloro.
[0380]
[0315] Embodiment 7.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the compounds is bromo.
[0381]
[0316] Embodiment 8.R 1a , R 1b , R 1c , and R 1dThe compound according to Embodiment 1, wherein at least one of the elements is iodine.
[0382]
[0317] Embodiment 9.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the components is a haloalkoxy.
[0383]
[0318] Embodiment 10.R 1a , R 1b , R 1c , and R 1d The compound according to Embodiment 1, wherein at least one of the compounds is trifluoromethoxy.
[0384]
[0319] Embodiment 11.R 1a However, the compound described in Embodiment 1 is trifluoromethyl.
[0385]
[0320] Embodiment 12.R 1b However, the compound described in Embodiment 1 is trifluoromethyl.
[0386]
[0321] Embodiment 13.R 1c However, the compound described in Embodiment 1 is trifluoromethyl.
[0387]
[0322] Embodiment 14.R 1d However, the compound described in Embodiment 1 is trifluoromethyl.
[0388]
[0323] Embodiment 15.R 1a However, the compound described in Embodiment 1 is trifluoromethoxy.
[0389]
[0324] Embodiment 16.R 1b However, the compound described in Embodiment 1 is trifluoromethoxy.
[0390]
[0325] Embodiment 17.R 1c However, the compound described in Embodiment 1 is trifluoromethoxy.
[0391]
[0326] Embodiment 18.R 1d However, the compound described in Embodiment 1 is trifluoromethoxy.
[0392]
[0327] Embodiment 19.R 2 However, -C(O)NR 3 R 4 The compound according to any one of Embodiments 1 to 18.
[0393]
[0328] Embodiment 20.R 3 and R 4 However, R 3 and R 4 The compound according to Embodiment 19, wherein together with the bonded nitrogen atom, it forms an unsubstituted or substituted heterocycle.
[0394]
[0329] Embodiment 21.R 3 and R 4 However, R 3 and R 4 The compound according to embodiment 19 or 20, wherein together with the bonded nitrogen atom, it forms an unsubstituted or substituted piperazinyl ring.
[0395]
[0330] Embodiment 22. Formula II
[0396] [ka]
[0397] (In the formula, - R 9 These are, respectively, independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8 , or hydrogen, - Each R 10These are independently unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -NR 3 R 4 , -OR 5 , or -SR 7 And, - A compound according to any one of Embodiments 1 to 21, or a pharmaceutically acceptable salt thereof, wherein m is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
[0398]
[0331] Embodiment 23. Formula III
[0399] [ka]
[0400] A compound of any one of Embodiments 1 to 22, or a pharmaceutically acceptable salt thereof.
[0401]
[0332] Embodiment 24. A compound that is (6-iodo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof.
[0402]
[0333] Embodiment 25. A compound that is piperazine-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone, or a pharmaceutically acceptable salt thereof.
[0403]
[0334] Embodiment 26. A compound that is piperazine-1-yl(6-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)methanone, or a pharmaceutically acceptable salt thereof.
[0404]
[0335] Embodiment 27. A compound which is (7,8-difluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-yl)(piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof.
[0405]
[0336] Embodiment 28. The compound according to any one of Embodiments 1 to 27, wherein the pharmaceutically acceptable salt is an acid addition salt.
[0406]
[0337] Embodiment 29. The compound according to any one of Embodiments 1 to 28, wherein the pharmaceutically acceptable salt is a hydrochloride salt.
[0407]
[0338] Embodiment 30. A pharmaceutical composition comprising a compound according to any one of Embodiments 1 to 29 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient in unit dosage form.
[0408]
[0339] Embodiment 31. A method for treating a medical condition, wherein the formula for the effective therapeutic amount is (I):
[0409] [ka]
[0410] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - R 2These are, respectively, independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, and -C(O)NR 3 R 4 -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8 , or -C(O)C(O)OR 8 And, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 , R 7 , and R 8 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a pharmaceutically acceptable salt thereof, however, (a)(i)R 1a , R 1b , R 1c , and R 1d (ii)R 1b (iii)R 2 Compounds in which -C(O)OtBu or -C(O)OCH2Ph are excluded. (b)R 1d When R is methyl, 2It is not 4-methoxybenzyl, (c)R 1a When is methyl, Cl, CN, or F, or R 1b When R is Br, 2 It is not methyl, -C(=O)H, -C(=O)Me, -C(=O)Et, or -C(=O)Ph. A method comprising the step of administering a compound, or a pharmaceutically acceptable salt thereof, to a subject requiring it.
[0411]
[0340] Embodiment 32. The method according to Embodiment 31, wherein the medical condition is a medical condition of the central nervous system.
[0412]
[0341] Embodiment 33. The method according to Embodiment 31 or 32, wherein the pathological condition is essential tremor.
[0413]
[0342] Embodiment 34. The method according to Embodiment 31 or 32, wherein the medical condition is a seizure.
[0414]
[0343] Embodiment 35. The method according to Embodiment 31 or 32, wherein the medical condition is a neurological disorder.
[0415]
[0344] Embodiment 36. The method according to Embodiment 31 or 32, wherein the medical condition is post-traumatic stress disorder.
[0416]
[0345] Embodiment 37. The method according to Embodiment 31 or 32, wherein the medical condition is a neurodegenerative disease.
[0417]
[0346] Embodiment 38. The method according to any one of Embodiments 31, 32, or 37, wherein the medical condition is Alzheimer's disease.
[0418]
[0347] Embodiment 39. The method according to any one of Embodiments 31, 32, or 37, wherein the disease condition is Huntington's disease.
[0419]
[0348] Embodiment 40. The method according to any one of Embodiments 31, 32, or 37, wherein the disease is amyotrophic lateral sclerosis.
[0420]
[0349] Embodiment 41. The method according to any one of Embodiments 31, 32, or 37, wherein the medical condition is spinocerebellar ataxia.
[0421]
[0350] Embodiment 42. The method according to any one of Embodiments 31, 32, or 37, wherein the medical condition is Parkinson's disease.
[0422]
[0351] Embodiment 43. The method according to Embodiment 31, wherein the medical condition is cognitive impairment.
[0423]
[0352] Embodiment 44. The method according to Embodiment 31 or 43, wherein the medical condition is stress-related.
[0424]
[0353] Embodiment 45. The method according to Embodiment 31 or 43, wherein the medical condition is related to aging.
[0425]
[0354] Embodiment 46. The method according to Embodiment 31 or 43, wherein the medical condition is memory loss.
[0426]
[0355] Embodiment 47. The method according to Embodiment 31 or 43, wherein the medical condition is related to a neurodegenerative disease.
[0427]
[0356] Embodiment 48. The method according to Embodiment 31 or 43, wherein the medical condition is related to post-traumatic stress disorder.
[0428]
[0357] Embodiment 49. The method according to Embodiment 31 or 43, wherein the medical condition is related to attention deficit hyperactivity disorder.
[0429]
[0358] Embodiment 50. The method according to Embodiment 31 or 43, wherein the medical condition is related to generalized anxiety disorder.
[0430]
[0359] Embodiment 51. The method according to Embodiment 31 or 43, wherein the medical condition is related to obsessive-compulsive disorder.
[0431]
[0360] Embodiment 52. The method according to Embodiment 31 or 43, wherein the medical condition is related to schizophrenia.
[0432]
[0361] Embodiment 53. The method according to Embodiment 31 or 43, wherein the medical condition is related to bipolar disorder.
[0433]
[0362] Embodiment 54. The method according to Embodiment 31 or 43, wherein the medical condition is related to major depressive disorder.
[0434]
[0363] Embodiment 55. The method according to Embodiment 31 or 43, wherein the medical condition is a heart condition.
[0435]
[0364] Embodiment 56. The method according to Embodiment 31 or 55, wherein the condition is characterized by an irregular heartbeat.
[0436]
[0365] Embodiment 57. The method according to any one of Embodiments 31, 55, or 56, wherein the medical condition is catecholamine-induced polymorphic ventricular tachycardia.
[0437]
[0366] Embodiment 58. The method according to Embodiment 31 or 55, wherein the medical condition is heart failure.
[0438]
[0367] Embodiment 59. The method according to any one of Embodiments 31, 55, or 58, wherein the medical condition is congestive heart failure.
[0439]
[0368] Embodiment 60. The method according to any one of Embodiments 31, 55, or 58, wherein the medical condition is chronic heart failure.
[0440]
[0369] Embodiment 61. The method according to any one of Embodiments 31, 55, or 58, wherein the condition is heart failure with reduced ejection fraction.
[0441]
[0370] Embodiment 62. The method according to any one of Embodiments 31, 55, or 58, wherein the condition is heart failure with maintained ejection fraction.
[0442]
[0371] Embodiment 63. The method according to any one of Embodiments 31, 55, or 58, wherein the subject is a heart failure patient having an implantable cardioverter-defibrillator, where the implantable cardioverter-defibrillator is implanted in the patient.
[0443]
[0372] Embodiment 64. The method according to any one of Embodiments 31, 55, or 58, wherein the medical condition is acute heart failure.
[0444]
[0373] Embodiment 65. The method according to any one of Embodiments 31, 55, or 58, wherein the subject is a heart failure patient who requires maintenance of cardiac function after myocardial infarction.
[0445]
[0374] Embodiment 66. The method according to any one of Embodiments 31, 55, or 58, wherein the medical condition is myocardial infarction.
[0446]
[0375] Embodiment 67. The method according to any one of Embodiments 31, 55, or 58, wherein the medical condition includes cardiac ischemia / reperfusion injury.
[0447]
[0376] Embodiment 68. The method according to Embodiment 31, wherein the medical condition is a musculoskeletal condition.
[0448]
[0377] Embodiment 69. The method according to Embodiment 31 or 68, wherein the medical condition is congenital myopathy.
[0449]
[0378] Embodiment 70. The method according to any one of Embodiments 31, 68, or 69, wherein the medical condition is RYR1-related myopathy.
[0450]
[0379] Embodiment 71. The method according to any one of Embodiments 31 or 68 to 70, wherein the medical condition is muscular dystrophy.
[0451]
[0380] Embodiment 72. The method according to any one of Embodiments 31 or 68 to 71, wherein the medical condition is Duchenne muscular dystrophy.
[0452]
[0381] Embodiment 73. The method according to Embodiment 31 or 68, wherein the medical condition is sarcopenia.
[0453]
[0382] Embodiment 74. The method according to Embodiment 31 or 68, wherein the medical condition is cancer-related muscle weakness.
[0454]
[0383] Embodiment 75. The method according to any one of Embodiments 31, 68, or 74, wherein the condition is cancerous cachexia.
[0455]
[0384] Embodiment 76. The method according to Embodiment 75, wherein the condition is cancer cachexia caused by cancer with bone metastases.
[0456]
[0385] Embodiment 77. The method according to Embodiment 31, wherein the patient's condition is diabetes.
[0457]
[0386] Embodiment 78. The method according to Embodiment 31, wherein the medical condition is malignant hyperthermia.
[0458]
[0387] Embodiment 79. The method according to any one of Embodiments 31 to 78, wherein the administration step is orally. Additional Embodiments
[0388] Embodiment 1A. Formula (IV):
[0459] [ka]
[0460] (In the formula, R 1 This is selected from the group consisting of halogens, haloalkyls, and haloalkyloxys. n is a compound represented by the structure (selected from the group consisting of 1, 2, 3, and 4), and its pharmaceutically acceptable salts.
[0461]
[0389] Embodiment 2A. The compound according to Embodiment 1A, in the form of a salt with a pharmaceutically acceptable acid or base.
[0462]
[0390] Embodiment 3A. The compound according to Embodiment 1A or 2A, wherein the salt is an acid addition salt.
[0463]
[0391] Embodiment 4A. The compound according to any one of Embodiments 1A to 3A, wherein the salt is a hydrochloride salt.
[0464]
[0392] Embodiment 5A.R 1 However, the compound is a haloalkyl compound as described in any one of Embodiments 1A to 4A.
[0465]
[0393] The compound according to any one of Embodiments 1A to 5A, wherein Embodiment 6A.n is 1.
[0466]
[0394] Embodiment 7A. The compound of formula (I) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0467] [ka]
[0468] .
[0469]
[0395] Embodiment 8A. The compound of formula (2) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0470] [ka]
[0471] .
[0472]
[0396] Embodiment 9A. The compound of formula (3) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0473] [ka]
[0474] .
[0475]
[0397] Embodiment 10A. The compound of formula (4) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0476] [ka]
[0477] .
[0478]
[0398] Embodiment 11A. The compound of formula (5) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0479] [ka]
[0480] .
[0481]
[0399] Embodiment 12A. The compound of formula (6) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0482] [ka]
[0483] .
[0484]
[0400] Embodiment 13A. The compound of formula (7) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0485] [ka]
[0486] .
[0487]
[0401] Embodiment 14A. The compound of formula (8) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0488] [ka]
[0489] .
[0490]
[0402] Embodiment 15A. The compound of formula (9) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0491] [ka]
[0492] .
[0493]
[0403] Embodiment 16A. The compound of formula (10) described in Embodiment 1A, or a pharmaceutically acceptable salt thereof.
[0494] [ka]
[0495] .
[0496]
[0404] Embodiment 17A. A pharmaceutical composition comprising a compound described in any one of Embodiments 1A to 16A in combination with one or more pharmaceutically acceptable excipients or carriers.
[0497]
[0405] Embodiment 18A. A method for treating or preventing a disorder, disease, or impairment of the nervous system, or for treating or preventing cognitive impairment, or for improving cognitive function, comprising the step of administering a therapeutically effective amount of a compound according to any of Embodiments 1A to 16A, or a pharmaceutical composition according to Embodiment 17A, to a subject in need of such treatment.
[0498]
[0406] Embodiment 19A. The method according to Embodiment 18A, wherein the medical condition, disease, or disorder is related to abnormal function of ryanodine receptor type 1, ryanodine receptor type 2, ryanodine receptor type 3, or a combination thereof.
[0499]
[0407] Embodiment 20A. The method according to Embodiment 18A or 19A, wherein the condition, disease, or disorder is a condition, disease, or disorder of the central nervous system (CNS) or the peripheral nervous system.
[0500]
[0408] Embodiment 21A. The method according to any one of Embodiments 18A to 20A, wherein the medical condition, disease, or disorder is selected from the group consisting of Alzheimer's disease (AD), post-traumatic stress disorder (PTSD), Huntington's disease (HD), neurological disorders, seizures, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), spinocerebellar ataxia (SCA), and Parkinson's disease (PD).
[0501]
[0409] Embodiment 22A. The method according to Embodiment 18A, wherein the cognitive impairment is stress-related or age-related, or the cognitive function to be improved is short-term memory, long-term memory, attention, or learning, or the cognitive impairment is related to a disease or disorder selected from the group consisting of Alzheimer's disease (AD), post-traumatic stress disorder (PTSD), attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), generalized anxiety disorder (GAD), obsessive-compulsive disorder (OCD), Parkinson's disease (PD), schizophrenia, bipolar disorder, and major depressive disorder.
[0502]
[0410] Embodiment 23A. The method according to any one of Embodiments 18A to 22A, wherein the compound is used in a dose sufficient to restore or enhance the binding of carstabin 2 to RyR2.
[0503]
[0411] Embodiment 24A. The method according to any one of Embodiments 18A to 22A, wherein the compound is used in a dose sufficient to restore or enhance the binding of carstabin 1 to RyR1.
[0504]
[0412] Embodiment 25A. The compound acts via the RyR channel Ca 2+ The method according to any one of embodiments 18A to 24A, used in a dose sufficient to reduce leakage.
[0505]
[0413] Embodiment 26A. A compound according to any one of Embodiments 1A to 16A, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to Embodiment 17A, for use in the treatment or prevention of a disorder, disorder, or disease of the nervous system, or for the treatment or prevention of cognitive impairment, or for improving cognitive function.
[0506]
[0414] Embodiment 27A. The compound according to Embodiment 26A, wherein the condition, disorder, or disease is a condition, disorder, or disease of the central nervous system (CNS) or the peripheral nervous system.
[0507]
[0415] Embodiment 28A. A method for preparing a compound according to any one of claims 1A to 16A, (a) Formula A'
[0508] [ka]
[0509] The compound is reacted with an acylating agent to produce equation (B'):
[0510] [ka]
[0511] (In the formula, R 1 The step of producing a compound of (and n as defined in claim 1, and X is a leaving group), (b) Compound (B') is reacted with optionally protected piperazine to obtain formula (C'').
[0512] [ka]
[0513] (In the formula, R 2 The steps include: producing a compound (which is an H or nitrogen protecting group), and (c) Optionally, a step of removing the nitrogen protecting group to produce the compound of formula (IV). A preparation method including the following.
[0514]
[0416] Embodiment 29A. A method for preparing a compound according to any one of claims 1A to 16A, (a) Formula A'
[0515] [ka]
[0516] The compound of formula
[0517] [ka]
[0518] Reacting with an acylated piperazine derivative, formula (C'')
[0519] [ka]
[0520] (In the formula, R 2The steps include: producing a compound (which is an H or nitrogen protecting group), and (b) Optionally, remove the nitrogen protecting group to produce the compound of formula (IV). A preparation method including the following.
[0521]
[0417] Embodiment 30A. Formula (I')
[0522] [ka]
[0523] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0524] [ka]
[0525] The compound is reacted with an acylating agent to produce formula (B):
[0526] [ka]
[0527] The step of producing a compound of (wherein X is a leaving group), (b) Compound (B) Formula NHR 3a R 4a When reacted with the amine, formula (C):
[0528] [ka]
[0529] (In the formula, R 3a R 3 or nitrogen protecting group, R 4a R 4 The steps of producing a compound (which is a nitrogen protecting group), and (c) Optionally, remove the nitrogen protecting group to produce the compound of formula (I'). A preparation method including the following.
[0530]
[0418] Embodiment 31A. Formula (I')
[0531] [ka]
[0532] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0533] [ka]
[0534] The compound of formula
[0535] [ka]
[0536] (In the formula, X is a leaving group, and R 3a R 3 or nitrogen protecting group, R 4a R 4 Alternatively, react with a compound of a nitrogen protecting group to produce formula (C):
[0537] [ka]
[0538] The steps of generating the compound, (b) Optionally, remove the nitrogen protecting group to produce the compound of formula (I'). A preparation method including the following.
[0539]
[0419] Embodiment 32A. Formula (II)
[0540] [ka]
[0541] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - R 9 These are, respectively, independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8 , or hydrogen, - Each R 10 These are independently unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -NR 3 R 4 , -OR 5 , or -SR 7 And, - The compound (where m is 0, 1, 2, 3, 4, 5, 6, 7, or 8) or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0542] [ka]
[0543] The compound is reacted with an acylating agent to produce formula (B):
[0544] [ka]
[0545] The step of producing a compound of (wherein X is a leaving group), (b) Compound (B)
[0546] [ka]
[0547] (In the formula, R 9a R 9 Alternatively, react with an amine (which is a nitrogen leaving group) to produce formula (C'):
[0548] [ka]
[0549] The steps of generating the compound, (c) Optionally, remove the nitrogen protecting group to produce the compound of formula (II). A preparation method including the following.
[0550]
[0420] Embodiment 33A. Formula (II)
[0551] [ka]
[0552] (In the formula, - Each R 1a , R 1b , R 1c , and R1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, - R 9 These are, respectively, independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8 , or hydrogen, - Each R 10These are independently unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, and -NR. 3 R 4 , -OR 5 , or -SR 7 And, - The compound (where m is 0, 1, 2, 3, 4, 5, 6, 7, or 8) or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0553] [ka]
[0554] The compound of formula
[0555] [ka]
[0556] (In the formula, X is a leaving group, and R 9a R 9 Alternatively, react with a compound of a nitrogen leaving group to produce formula (C'):
[0557] [ka]
[0558] The steps of generating the compound, (b) Optionally, remove the nitrogen protecting group to produce the compound of formula (II). A preparation method including the following.
[0559]
[0421] Embodiment 34A. Formula (III)
[0560] [ka]
[0561] (In the formula, - Each R 1a , R 1b , R 1c , and R 1d These are independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 , -OR 5 -SO3H, -SO2R 6 , -OSO2R 6 ,-S(O)R 6 , or -SR 7 , or hydrogen or halogen, - Each R 3 and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0562] [ka]
[0563] The compound of formula
[0564] [Chemical formula]
[0565] (where X is a leaving group and R 9a is hydrogen or a nitrogen protecting group) is reacted with a compound of formula (C’);
[0566] [Chemical formula]
[0567] to produce a compound of formula (C’), and (b) When R 9a is a nitrogen protecting group, removing the nitrogen protecting group to produce a compound of formula (III) A preparation method comprising.
[0568]
[0422] Embodiment 35A. Formula (III)
[0569] [Chemical formula]
[0570] (where - Each R 1a 、R 1b 、R 1c 、and R 1d is independently, each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO2, -N3, -NR 3 R 4 、-OR 5 、-SO3H、-SO2R 6 、-OSO2R 6 、-S(O)R 6 、or -SR 7 、or hydrogen or halogen, - Each R 3and R 4 Each is independently a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 R 3 and R 4 Together with the nitrogen atom to which it is bonded, it forms an unsubstituted or substituted heterocycle or aromatic heterocycle. - Each R 5 , R 6 and R 7 These are compounds of alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, each independently substituted or unsubstituted. or a method for preparing a pharmaceutically acceptable salt thereof, (a) Formula A
[0571] [ka]
[0572] The compound is reacted with an acylating agent to produce formula (B):
[0573] [ka]
[0574] The step of producing a compound of (wherein X is a leaving group), (b) Compound (B)
[0575] [ka]
[0576] (In the formula, X is a leaving group, and R 9a(C') is reacted with piperazine protected by an optional hydrogen or nitrogen protecting group to produce equation (C');
[0577] [ka]
[0578] The steps of generating the compound, (c)R 9a When is a nitrogen protecting group, the step of removing the nitrogen protecting group to produce the compound of formula (III) A preparation method including the following.
Claims
1. Formula (I): 【Chemistry 1】 (In the formula, - Each R 1a , R 1b , R 1c , and R 1d are independently each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -CN, -NO 2 , -N 3 , -NR 3 R 4 , -OR 5 , -SO 3 H, -SO 2 R 6 , -OSO 2 R 6 , -S(O)R 6 , or -SR 7 or hydrogen or a halogen; - R 2 each independently represents a substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, heterocyclyl, -C(O)NR 3 R 4 , -C(O)C(O)NR 3 R 4 , -C(O)R 8 , -C(O)OR 8 or -C(O)C(O)OR 8 and - Each R 3 and R 4 are independently, each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen, or R 3 and R 4 is R 3 and R 4 together with the nitrogen atom to which it is attached form an unsubstituted or substituted heterocyclic or aromatic heterocyclic ring, - Each R 5 , R 6 , R 7 , and R 8 are independently each independently substituted or unsubstituted alkyl, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heteroaryl, or heterocyclyl, or hydrogen or halogen; or a pharma- ceutically acceptable salt thereof, however, (a)(i)R 1a , R 1b , R 1c , and R 1d are each hydrogen; (ii) R 1b is OH or methoxy, or (iii) R 2 -C(O)OtBu or -C(O)OCH 2 Compounds with a pH of 1.0 or less are excluded. (b) R 1d is methyl, R 2 is not 4-methoxybenzyl, (c) R 1a is methyl, Cl, CN, or F, or R 1b When is Br, R 2 is not methyl, -C(=O)H, -C(=O)Me, -C(=O)Et, or -C(=O)Ph or a pharma- ceutically acceptable salt thereof.
2. R 1a , R 1b , R 1c , and R 1d The compound of claim 1 , wherein at least one of is haloalkyl.
3. R 1a , R 1b , R 1c , and R 1d The compound of claim 1 , wherein at least one of is trifluoromethyl.
4. R 1a , R 1b , R 1c , and R 1d The compound of claim 1 , wherein at least one of is a halogen.
5. R 1d The compound of claim 1 , wherein is trifluoromethyl.
6. R 2 is -C(O)NR 3 R 4 2. The compound of claim 1,
7. R 3 and R 4 But, R 3 and R 4 The compound of claim 6 , wherein, together with the nitrogen atom to which it is attached, forms an unsubstituted or substituted heterocycle.
8. R 3 and R 4 But, R 3 and R 4 The compound of claim 6 , wherein, together with the nitrogen atom to which it is attached, forms an unsubstituted or substituted piperazinyl ring.
9. Formula II 【Chemistry 2】 (In the formula, - R 9 each independently represents a substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -C(O)NR 3 R 4 , -C(O)R 8 , or -C(O)OR 8 or hydrogen, - Each R 10 are independently selected from unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, benzyl, heterocyclyl, heteroaryl, -NR 3 R 4 , -OR 5 , or -SR 7 and - m is 0, 1, 2, 3, 4, 5, 6, 7, or 8, or a pharma- ceutically acceptable salt thereof.
10. Formula III 【Chemistry 3】 2. The compound of claim 1, which is a compound of the formula:
11. The compound of claim 1, wherein the compound is: (6-iodo-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)(piperazin-1-yl)methanone; Piperazin-1-yl(8-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; Piperazin-1-yl(6-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; (7,8-difluoro-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)(piperazin-1-yl)methanone; Piperazin-1-yl(7-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; Piperazin-1-yl(9-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; Piperazin-1-yl(7-(trifluoromethoxy)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; Piperazin-1-yl(6-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone; (6-chloro-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)(piperazin-1-yl)methanone; or (6-Bromo-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)(piperazin-1-yl)methanone.
12. The compound according to claim 1, wherein the compound is piperazin-1-yl(7-(trifluoromethyl)-2,3-dihydrobenzo[f][1,4]thiazepin-4(5H)-yl)methanone, or a pharma- ceutically acceptable salt thereof.
13. 13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof, and a pharma- ceutically acceptable excipient in unit dosage form.
14. A pharmaceutical composition for use in treating a medical condition in a subject, comprising a compound according to any one of claims 1 to 12.
15. 15. The pharmaceutical composition of claim 14, wherein the condition is a central nervous system condition.
16. 15. The pharmaceutical composition of claim 14, wherein the condition is essential tremor.
17. The pharmaceutical composition of claim 14, wherein the condition is associated with cognitive impairment.
18. 15. The pharmaceutical composition of claim 14, wherein the condition is a cardiac condition.
19. 15. The pharmaceutical composition of claim 14, wherein the condition is catecholaminergic polymorphic ventricular tachycardia.
20. The pharmaceutical composition of claim 14, wherein the condition is heart failure.
21. 15. The pharmaceutical composition of claim 14, wherein the condition is heart failure with reduced ejection fraction.
22. 15. The pharmaceutical composition of claim 14, wherein the condition is a musculoskeletal condition.
23. The pharmaceutical composition of claim 14, wherein the condition is an RYR1-associated myopathy.
24. 15. The pharmaceutical composition of claim 14, wherein the condition is Duchenne muscular dystrophy.
25. The pharmaceutical composition of claim 14, wherein the condition is sarcopenia.
